



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A01N 43/00, 43/04, A61K 48/00, C12N 15/00, 15/09, 15/63, 15/70, 15/74, 5/00, C07H 21/02, 21/04		A1	(11) International Publication Number: WO 97/36481
			(43) International Publication Date: 9 October 1997 (09.10.97)
(21) International Application Number: PCT/US97/05272		(74) Agent: BERLINER, Robert; Robbins, Berliner & Carson, L.L.P., 5th floor, 201 North Figueroa Street, Los Angeles, CA 90012-2628 (US).	
(22) International Filing Date: 26 March 1997 (26.03.97)			
(30) Priority Data:		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
60/015,555 2 April 1996 (02.04.96) US			
08/822,516 24 March 1997 (24.03.97) US			
(60) Parent Application or Grant			
(63) Related by Continuation			
US Not furnished (CIP)			
Filed on Not furnished			
(71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(72) Inventors; and			
(75) Inventors/Applicants (for US only): CORBEAU, Pierre [-/US]; 7834 Camino Raposa, San Diego, CA 92122 (US). KRAUS, Gunter [-/US]; 3048 Shipping Avenue, Miami, FL 33133 (US). WONG-STAAAL, Flossie [-/US]; 12737 Monterey Cypress Way, San Diego, CA 92130 (US).			

**(54) Title: DESIGN OF NOVEL HIGHLY EFFICIENT HIV BASED PACKAGING SYSTEMS FOR GENE THERAPY**

**(57) Abstract**

By transducing cells with an HIV-1-MN molecular clone deleted in the major packaging sequence, a stable HIV-1 packaging cell line,  $\psi$  422 was produced.  $\psi$  422 cells form syncytia with CD4 positive cells, correctly express HIV-1 structural proteins, and produce large amounts of mature particles with normal RT activity. These particles are not infectious. When stably transfected with an HIV-based retroviral vector, the  $\psi$  422 cell line produces hybrid virions capable of transducing CD4 positive cells with high efficiency (e.g.,  $10^5$  cells/ml). The availability of this stable, noninfectious HIV-1 packaging cell line capable of generating high titer HIV vectors enables the use of HIV-1 based nucleic acids delivery systems, for example, in gene therapy. An HIV-2 based vector is packaged by the packaging cell lines, demonstrating that HIV-2 cell transformation vectors are packaged by the packaging cell line. HIV based vectors packaged by the high efficiency cell lines are shown to have anti-HIV activity *per se*.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	R	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## DESIGN OF NOVEL HIGHLY EFFICIENT HIV BASED PACKAGING SYSTEMS FOR GENE THERAPY

### 5 Cross Reference to Related Applications:

This application is a continuation-in-part of U.S. provisional patent application USSN 60 015,555, by Corbeau *et al.*, filed April 2, 1996, which is incorporated herein by reference for all purposes.

### BACKGROUND OF THE INVENTION

10 The primate lentiviruses human immunodeficiency virus (HIV) type 1 (HIV-1), and type 2 (HIV-2) cause the disease AIDS, and are epidemic in human populations world wide. HIV-1 and HIV-2 are genetically related, antigenically cross reactive, and share a common cellular receptor (CD4). See, Rosenberg and  
15 Fauci (1993) in *Fundamental Immunology, Third Edition* Paul (ed) Raven Press, Ltd., New York (Rosenberg and Fauci 1) and the references therein for an overview of HIV infection.

The surface glycoprotein CD4 is found mainly on a subset of T cells, monocytes, macrophage and some brain cells. HIV has a lipid envelope with viral antigens that bind the CD4 receptor, causing fusion of the viral membrane  
20 and the target cell membrane and release of the HIV capsid into the cytosol. HIV corrupts the cellular machinery of infected cells by causing the cell to replicate copies of the HIV virus, and eventually death of infected immune cells, thereby disabling the immune system and killing the patient due to complications associated with a disabled immune system. HIV infection also spreads directly from cell to  
25 cell, without an intermediate viral stage. During cell-cell transfer of HIV, a large amount of viral glycoprotein is expressed on the surface of an infected cell, which binds CD4 receptors on uninfected cells, causing cellular fusion. This typically produces an abnormal multinucleate syncytial cell in which HIV is replicated and normal cell functions are suppressed.

30

Due to the pandemic spread of HIV, an intense world-wide effort to unravel the molecular mechanisms and life cycle of these viruses is underway. It is now clear that the life cycle of these viruses provides many potential targets for inhibition by gene therapy, including cellular expression of transdominant mutant *gag* and *env* nucleic acids to interfere with virus entry, TAR (the binding site for *tat*, which is typically required for transactivation) decoys to inhibit transcription and trans activation, and RRE (the binding site for Rev; *i.e.*, the Rev Response Element) decoys and transdominant Rev mutants to inhibit RNA processing. See, Wong-Staal *et al.*, PCT/US94/05700, and Rosenberg and Fauci (1993) in *Fundamental Immunology, Third Edition* Paul (ed) Raven Press, Ltd., New York and the references therein for an overview of HIV infection and the HIV life cycle. Gene therapy vectors utilizing ribozymes, antisense molecules, decoy genes, transdominant genes and suicide genes, including retroviruses are found in Wong-Staal *et al.*, *id*, and Yu *et al.*, *Gene Therapy* (1994) 1:13-26. Antisense and ribozyme therapeutic agents are of increasing importance in the treatment and prevention of HIV infection.

In previous studies, the efficacy of several anti-HIV-1 hairpin ribozymes in inhibiting virus replication in human T cell lines was demonstrated. See, Wong-Staal *et al.*, PCT/US94/05700; Yamada *et al.*, *Virology* (1994) 205:121-126; Yamada *et al.*, *Gene Therapy* (1994) 1:38-45; Yu *et al.*, *Proc Natl. Acad. Sci. USA* (1993) 90:6340-6344, and Yu *et al.*, *Virology* (1995) 206:381-386. With an anti-U5 ribozyme which targets a highly conserved region of the HIV-1 genome, it was shown that intracellular immunization of primary lymphocytes or hematopoietic progenitor cells lead to resistance of both lymphotropic and macrophage tropic HIV-1 strains (Leavitt *et al.*, *Hum. Gene Ther.* (1994) 5:1115-1120; Yu *et al.*, *Proc. Natl. Acad. Sci. USA* (1995) 92:699-703).

Recent studies of the dynamics of HIV replication in patients under antiviral therapy have reaffirmed the central role of the virus in disease progression, and provided a strong rationale for the development of effective, long term antiviral therapy (Coffin, J. M. *Science* (1995) 267:483-489; Ho *et al.*, *Nature* (1995) 373:123-6; Wei *et al.*, *Nature* (1995) 373:117-22). One interesting

parameter from these studies is the extremely short life span of an HIV-1 infected CD4<sup>+</sup> lymphocyte (half life = 1-2 days), contrasting data from other studies which gave an estimated lifespan of months to years for uninfected lymphocytes (Bordignon *et al.*, *Hum Gene Ther.* (1993) 4:513-20). These observations are  
5 relevant for antiviral gene therapy, because a cell resistant to viral infection, or which suppresses viral replication are strongly selected for *in vivo*.

Gene therapeutic approaches are hampered by the limitations of the delivery systems currently used in gene therapy. For instance, the extensively used murine retroviral vectors transduce human peripheral blood lymphocytes poorly,  
10 and fail to transduce non-dividing cells such as monocytes/macrophages, which are known to be reservoirs for HIV. An appealing alternative would be to utilize HIV-based delivery systems, which would ensure optimal cell targeting and intracellular co-localization of HIV and anti-HIV therapeutics.

Gene therapeutics can target, *inter alia*, viral RNAs (*e.g.*, using  
15 ribozymes, or antisense RNA), viral proteins (RNA decoys, transdominant viral proteins, intracellular single chain antibodies, soluble CD4), infectible cells (suicide genes), or the immune system (*in vivo* immunization). However, these various gene therapeutic approaches are hampered by the limitations of the delivery systems currently used in gene therapy. For instance, with regard to HIV  
20 treatment, the extensively used murine retroviral vectors transduce (transfer nucleic acids into) human peripheral blood lymphocytes poorly, and fail to transduce non-dividing cells such as monocytes/macrophages, which are known to be reservoirs for HIV. An appealing alternative basis for gene therapy vectors would be to utilize HIV-based delivery systems, which would ensure optimal CD4<sup>+</sup> cell  
25 targeting and intracellular co-localization of HIV target and gene therapeutic effector molecules. In addition, HIV-derived vectors could be packaged by the wild type virions of patients *in vivo* and thereby be replicated and disseminated to a larger pool of potentially HIV-infectible cells upon infection by HIV.

Finally, HIV cell transformation vectors are particularly desirable  
30 because of their ability to be pseudotyped to infect non-dividing hematopoietic stem cells (CD34<sup>+</sup>). These stem cells differentiate into a variety of immune cells,

including CD4<sup>+</sup> cells which are the primary targets for HIV infection. CD34<sup>+</sup> cells are the most important target cells for *ex vivo* gene therapy, because these cells differentiate into many different cell types, and because the cells are capable of re-engraftment into a patient undergoing *ex vivo* therapy.

- 5                   Most of the previously reported HIV packaging systems have very low titers, ranging from 10<sup>0</sup> to 10<sup>2</sup> transducing units per ml (TU/ml), and/or result from transient transfections, which are unstable (Buchsacher, *et al.* (1992) *J. Virol.* 66(5):2731-2739; Rizvi, *et al.* (1993) *J. Virol.* 67(5):2681-2688; Carroll, *et al.* (1994) *J. Virol.* 68(9):6047-6051; Parolin, *et al.* (1994) *J. Virol.* 68(6):3888-3895; Shimada, *et al.* (1991) *J. Clin. Invest.* 88:1043-1047). A group reported a transduction efficiency of 2x10<sup>4</sup> TU/ml, but in this study the packaging system was infectious wild type HIV-1 (Richardson, *et al.* (1993) *J. Virol.* 67(7):3997-4005), which is of little practical value. The only study describing a stable cell line doubly transfected with the packaging plasmid and the vector reported transduction lower than 10<sup>2</sup> TU/ml (Carroll, *et al.* (1994) *J. Virol.* 68(9):6047-6051).

Thus, the efforts to develop HIV-based delivery systems have so far resulted in extremely low transduction efficiencies for HIV-based vectors (Buchsacher, *et al.* (1992) *J. Virol.* 66(5):2731-2739; Richardson, *et al.* (1993) *J. Virol.* 67(7):3997-4005; Rizvi, *et al.* (1993) *J. Virol.* 67(5):2681-2688; Carroll, *et al.* (1994) *J. Virol.* 68(9):6047-6051), rendering the use of HIV delivery systems impractical. This invention overcomes these and other problems. In addition, it is discovered that the regulatory elements which are used in HIV vectors (*e.g.* TAR, RRE and packaging signal sequences) are themselves antagonistic to HIV replication, thereby providing a level of HIV inhibition.

### SUMMARY OF THE INVENTION

The invention derives from the discovery of vectors and cell lines which provide efficient packaging of HIV-packageable nucleic acids, useful, *inter alia* as gene therapeutic agents. A variety of packaging vectors and stable non-infectious HIV packaging cell lines are provided, with typical packaging titers of

10<sup>4</sup> to 10<sup>6</sup> transducing units per ml, enabling efficient transduction of CD4<sup>+</sup> cells with HIV-based gene therapy vectors. Thus, this invention provides for the making and use of packaged HIV-packageable nucleic acids for the transduction of CD4<sup>+</sup> cells, including the use of HIV-packageable nucleic acids as gene therapy  
5 vectors.

In one class of embodiments, a high efficiency packaging vector comprising a high efficiency packaging vector nucleic acid or nucleic acids is provided. In addition to the packaging nucleic acid, a packaging vector optionally includes additional components such as proteins, lipids and carbohydrates which  
10 are optionally arranged to facilitate delivery of the packaging vector nucleic acid into a cell. For instance, the packaging vector optionally comprises a viral particle surrounding the nucleic acid. Thus, the packaging vector may be a nucleic acid, *e.g.*, a plasmid, or a nucleic acid with associated material such as a nucleic acid encapsulated in a viral delivery capsid (*i.e.*, a viral vector unrelated to HIV, such  
15 as adeno virus, adeno-associated virus, pox virus, or the like).

The high efficiency packaging vector nucleic acid of the vector encode some or all of the proteins needed to produce an HIV-1 particle. Typically, packaging vector nucleic acids are derived from an HIV viral genome, or a portion thereof. Packaging vector nucleic acids lack the nucleic acids  
20 necessary for packaging of an RNA corresponding to the packaging vector nucleic acid into an HIV capsid. That is, packaging vector nucleic acids are not themselves encapsulated in the HIV particles which they encode, *i.e.*, the high efficiency packaging vector nucleic acids are not themselves infective. Typically, nucleic acids corresponding to one or more, and preferably two or more, stem  
25 loops of the  $\Psi$  structure are deleted or altered in the packaging vector relative to the wild-type HIV genomic RNA nucleic acid. The particles encoded by the high efficiency packaging vector nucleic acids of the invention typically package the packaging vector nucleic acid at a level less than 10%, and more typically less than 1%, of the level that they package a nucleic acid which has a wild-type HIV  
30 packaging site. The level of nucleic acid incorporation is optionally, and typically, measured by RT-PCR. The nucleic acid preferably encodes the accessory gene

*vpr.* In one preferred embodiment, the packaging vector nucleic acid is derived from an HIV-1-MN genomic clone, *e.g.*, by standard cloning or mutagenesis techniques. For example, the plasmid  $\Delta\Psi$  is an example preferred HIV-1-MN derived packaging vector.

5 Many promoters are useful in the high efficiency packaging vector nucleic acid, including known inducible and constitutive promoters. One preferred promoter comprises the 5' HIV LTR, which is induced, *inter alia*, in response to HIV infection. Where the packaging vector nucleic acid comprises an HIV LTR, the vector typically includes a deletion in the HIV packaging site located between  
10 the 5' LTR and the GAG gene as compared to a wild-type HIV virus.

In one preferred embodiment, the vector comprises only a portion of the nucleic acids which encode components used to make an HIV particle. Although it is possible to place all of the sequences necessary for generating HIV capsids in a single packaging vector nucleic acid, placing the sequences in multiple  
15 discreet packaging vectors increases the safety of any packaging cell line created using a packaging vector or packaging vectors. This is because there is a lowered probability of recombination events between the packaging vector nucleic acids and any HIV-packageable nucleic acid which is present in a packaging cell inadvertently resulting in an infective virus.

20 A high efficiency packaging vector nucleic acid, when transfected into a cell, renders the cell competent to package HIV packageable RNA at a titre of at least about  $10^4$  transducing units per ml (TU), and often about  $10^5$  to  $10^6$  TU. A preferred packaging cell type stably transformed by the packaging vector is the Hela cell line.

25 When expressed in a cell, the particle encoded by packaging vector nucleic acid(s) comprises reverse transcriptase activity. Because the particles do not package packaging vector RNA, the particles are typically non-infectious. However, if expressed in a cell which also expresses wild-type genomic HIV RNA, the particles package the wild type HIV RNA, resulting in an infective HIV virus.

30 One advantage of an HIV-based anti-HIV vector is that the vector nucleic acid is



packaged by wild-type HIV during infection of a cell and disseminated to other cells in conjunction with the infecting HIV virus.

In certain preferred embodiments where the high efficiency packaging vector nucleic acid is derived from an HIV-1-MN genomic clone, nucleic acids encoded by the high efficiency packaging vector hybridize to nucleic acids encoded by an HIV-1-MN clone under stringent hybridization and wash conditions for the particular hybridization assay (typically a Southern or northern assay).

In one class of embodiments, a packaging vector as described above is used to transform a cell line to produce a high efficiency packaging cell line. The high efficiency packaging cell line typically produces at least about  $10^4$  transducing HIV vector particles (*i.e.*, particles containing HIV-packageable RNA) per ml, when the packaging cell line is transduced with an HIV-packageable nucleic acid. In preferred embodiments, the cell line produces at least about  $10^5$  transducing HIV vector particles per ml. In more preferred embodiments, the packaging cell line produces at least about  $10^6$  transducing HIV particles per ml.

The cell lines of the invention optionally comprise additional heterologous elements in addition to the packaging vector nucleic acid. For example, the incorporation of proteins into HIV-based retroviral particles can expand the host range of the viral particle. Accordingly, the cells optionally comprise such proteins, or nucleic acids encoding the proteins. The packaging cells optionally further include HIV-packageable nucleic acids.

The packaging cell lines of the invention are typically stable and non-infectious. In one preferred class of embodiments, the cell line is derived from the Hela cell line. One preferred Hela packaging cell line is the  $\Psi$ -422 cell line described herein. Thus, the invention provides both methods for making a stable packaging cell line, and cell lines produced by the methods. Supernatants from the cell lines are also provided. In preferred embodiments, the cell line is made before any HIV-packageable nucleic acid is introduced into the cell. Thus, in preferred embodiments, the packaging vector and the HIV-packageable nucleic acid are not co-transfected into a cell line. It is now discovered that separate

transfection of the packaging vector and the packageable nucleic acid reduces the likelihood of a recombination event resulting in an infective HIV particle. In addition, once a cell line is stably transformed with a packaging vector, the cell line can be used to package essentially any nucleic acid which includes an HIV packaging site. Thus, transforming a cell with a packaging vector prior to  
5 introducing a packageable nucleic acid into the cell line simplifies the logistics of making several separate cell lines, each of which packages, *e.g.*, a separate packageable nucleic acid.

Cell supernatants from the packaging cell lines are also a feature of  
10 the invention. The supernatant from a packaging cell line includes HIV particles which comprise an HIV packageable nucleic acid. The concentration of such particles is typically at least about  $10^3$  or  $10^4$  to about  $10^5$  transducing units per ml or more, more preferably at least about  $10^4$  to about  $10^6$  transducing units per ml or more, and most preferably at least about  $10^5$  transducing units per ml or more.  
15 In one embodiment, the invention provides a cell supernatant comprising an HIV-based vector produced by a method of manufacturing the supernatant. In the method, a target nucleic acid is incubated in a packaging cell line having a packaging vector nucleic acid which encodes an HIV-1 particle (the packaging vector typically has the Vpr accessory genes of HIV-1). The particle, when  
20 expressed, comprises reverse transcriptase activity, is non-infectious, and is competent to package RNA with a titre of at least  $10^4$  transducing units per ml, wherein the RNA has an HIV-1 packaging site, the particles do not package the packaging vector nucleic acids as detected by RT-PCR, and, the packaging vector comprises a deletion of more than one stem loop of the  $\Psi$  structure. The target  
25 nucleic acid is packaged in the cell into an HIV-1 particle, producing a packaged target nucleic acid and the cells are cultured to produce a cell supernatant comprising the packaged target nucleic acid.

In one embodiment, the present invention provides a method of transducing a target cell with an HIV-packageable target nucleic acid. In the  
30 method, a packaging cell line made as set forth herein is used to package a packageable target nucleic acid into an HIV particle. The HIV particle is then

incubated with the target cell, thereby transducing the target cell (typically a CD4<sup>+</sup> cell) with the target packageable nucleic acid. In this method, the target cell is ordinarily CD4<sup>+</sup>, since the target packageable nucleic acid gains entry to the target cell by interaction between the HIV particle packaging the target nucleic acid and the target cell (CD4 is the cellular receptor which recognizes the HIV particle).  
5 However, HIV particles transduce some CD4<sup>-</sup> cells *in vitro*. In addition, HIV particles are pseudotyped to transduce many other cell types, including hematopoietic stem cells (CD34<sup>+</sup>), which are also preferred cellular targets.

In one preferred embodiment, the transformation of the target cell with the target packageable nucleic acid renders the target cell resistant to HIV infection. This is accomplished by encoding an anti-HIV viral inhibitor in the target packageable nucleic acid, such as an anti-HIV ribozyme, transdominant gene, or suicide gene. Thus, the invention is useful, *inter alia*, in providing methods of transforming cells, and in rendering cells HIV resistant.  
10 HIV resistant cells are useful *in vitro* to reduce the risk of handling cells, *e.g.*, in tissue culture techniques, and in *ex vivo* and in *in vivo* gene therapy procedures.

One aspect of the present invention is the discovery that the HIV-2 packaging site is competent to be packaged by an HIV-1 packaging cell line. In other words, the HIV-1 *gag* proteins package nucleic acids comprising an HIV-2 packaging site. Thus, the invention provides HIV-2 derived nucleic acids packaged into viral particles containing HIV-1 *gag* proteins to yield a cell transformation vector. HIV packageable HIV-2 derived nucleic acids include an HIV-2 packaging site, and optionally other HIV-2 elements such as HIV-2 LTRs, polymerase genes, structural genes and the like. The use of HIV-2 derived nucleic acids in HIV-1  
20 particles provides a particularly preferred cell transformation vector, because HIV-2 nucleic acids do not typically recombine with HIV-1 nucleic acids, making the HIV-2 based nucleic acids safer than those which incorporate HIV-1 derived nucleic acids.

A particularly preferred HIV-2 clone to use as a source for HIV-2 nucleic acid elements is the HIV-2<sub>KR</sub> clone. In particular, the HIV-2<sub>KR</sub> LTRs are Rev independent, and the HIV-2<sub>KR</sub> packaging site is packaged by HIV-1 particles,  
30

*e.g.* in an HIV packaging cell. In addition, the clone has low pathogenicity and is infective in HIV model animals such as macaques.

In one particularly preferred embodiment, the HIV-2 derived nucleic acid packaged by the HIV-1 particle has a nuclear export signal. For instance, the MPMV nucleic acid nuclear export subsequence is a preferred nuclear export signal. The use of a nuclear export signal eliminates the need for Rev in transport of HIV-derived nucleic acid from the nucleus to the cytoplasm of a cell where they are translated. In other embodiments, an RRE or partial RRE signal is provided for co-localization of a therapeutic vector and an HIV target nucleic acid.

The cell transformation vectors of the invention typically include transcription cassettes which are expressed by the cell to be transformed. The transcription cassettes preferably include constitutive promoters such as pol III promoters (*e.g.*, those from the t-RNA genes, such as t-RNA<sup>Val</sup>) or pol II promoters (*e.g.*, strong promoters such as those derived from structural genes such as actin, or viral genes such as those found in adenovirus), or utilize the natural promoters found in an HIV LTR. The transcription cassettes comprise genes of interest such as therapeutic nucleic acids (*e.g.*, ribozymes and anti-sense molecules), suicide genes, transdominant genes, cellular enzymes and the like. In addition, HIV vectors are found to have intrinsic anti-HIV activity. The transcription cassettes are cloned between HIV-2 LTRs, or into the LTRs to reduce promoter interference. In one preferred embodiment, multiple transcription cassettes are included in the nucleic acid, some located internal to the LTRs and some between the LTRs of the cell transformation vector.

Accordingly, the invention also provides ways of transforming a cell, *e.g.* using the cell transformation vectors of the invention. In general, the cell transformation vectors of the invention are contacted to a target cell, permitting transduction of the nucleic acid encoded by the vector into the cell. The nucleic acid is then expressed, or is incorporated into the cellular genome, *e.g.* by HIV-2 LTRs which are part of the vector. The cells are typically isolated from a cell culture or a mammal. They are optionally reintroduced into a mammal after transduction by a cell transformation vector.

In one embodiment, the cells transformed are hematopoietic stem cells such as CD34<sup>+</sup> stem cells. Stem cells transformed by the methods are typically introduced into a mammal. In one particular embodiment, the cell transformation encodes an anti-HIV agent such as a ribozyme which cleaves an HIV nucleic acid. In this embodiment, cells transformed with the vectors and their differentiated progeny are HIV-resistant.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the structures of the  $\Delta\Psi$  packaging plasmid and the V653gpt vector. The position of the major splice donor site (MSD), and of the Rev Responsive Element (RRE) are indicated.

Figure 2 is a diagram of the construction of the  $\Delta\Psi$  packaging plasmid.

Figure 3 shows the non-infectivity of the T422 and g cell (packaging cells transduced with a packageable nucleic acid) line supernatants. Quadruplicate cultures of Molt4/8 cells exposed to various amounts (0.1 to 1,000 pg of p24 antigen) of wild type HIV-1-MN (4) or mutant (T422,n; gV,O; gZ,A) virions were tested at day 14 for HIV-1 infection by p24 capture assay. The, percentage of cultures which were HIV p24 positive is represented for each viral input.

Figure 4 shows the structure of basic HIV-2 gene delivery vectors. IP indicates an internal promoter; the marker gene is neo or x-gpt. The 340 stands for the MPMV sequence.

Figure 5 shows the structure of a rev and rre independent double copy vector. Stripes indicate the inserted pol III promoter and gene cassette.

Figure 6 shows the construction of HIV-2 double copy vectors. pLTR plasmid was digested with Age I and the overhang was filled in. A t-RNAval+Ribozyme cassette was inserted (See, WO 94/26877). The plasmid was digested with Cla I and the insert from the vector was cloned into the Cla I site.

Figure 7 is a schematic drawing depicting certain advantages to HIV-based anti-viral vectors.

Figure 8, panels A and B, provide schematic drawings of plasmids described in the examples.

### DEFINITIONS

5 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton *et al.* (1994) *Dictionary of Microbiology and Molecular Biology*, second edition, John Wiley and Sons (New York) provides one of skill with a general dictionary of many of the terms used in  
10 this invention. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described. For purposes of the present invention, the following terms are defined below.

A "vector" is a composition which can transduce, transform or  
15 infect a cell, thereby causing the cell to express nucleic acids and/or proteins other than those native to the cell, or in a manner not native to the cell. A vector includes a nucleic acid (ordinarily RNA or DNA) to be expressed by the cell (a "vector nucleic acid"). A vector optionally includes materials to aid in achieving entry of the nucleic acid into the cell, such as a viral particle, liposome, protein  
20 coating or the like. A "cell transformation vector" is a vector which encodes a nucleic acid capable of transforming a cell once the nucleic acid is transduced into the cell.

A "packaging vector" is a vector which encodes components necessary for production of HIV particles by a cell transduced by the packaging  
25 vector. The packaging vector optionally includes all of the components necessary for production of HIV particles, or optionally includes a subset of the components necessary for HIV packaging. For instance, in one preferred embodiment, a packaging cell is transformed with more than one packaging vector, each of which has a complementary role in the production of an HIV particle.

30 Two (or more) HIV-based packaging vectors are "complementary" when they together encode all of the functions necessary for HIV packaging, and

when each individually does not encode all of the functions necessary for packaging. Thus, *e.g.*, when two vectors transduce a single cell and together they encode the information for production of HIV packaging particles, the two vectors are "complementary". The use of complementary vectors is preferred because it  
5 increases the safety of any packaging cell made by transformation with a packaging vector by reducing the possibility that a recombination event will produce an infective virus.

Packaging vectors encode HIV particles. The HIV particles are competent to package target RNA which has an HIV packaging site. "High  
10 efficiency packaging vectors" package target RNAs such that packaging cells stably transformed with the packaging vector and transformed with a target packageable nucleic acid corresponding to the target packageable RNA produce packaged target RNA at a titer of at least about  $10^3$  or  $10^4$  to about  $10^5$  transducing units per ml or more, more preferably at least about  $10^4$  to about  $10^6$  transducing units per ml or  
15 more, and most preferably at least about  $10^5$  transducing units per ml or more. The precise titer which is produced varies depending on the nature of the packageable nucleic acid. For example, the minimal plasmid VOgpt is packaged less efficiently than the plasmid V653gpt (*see*, the examples herein), because it does not have as complete a packaging site. Thus, higher infectivities are typically  
20 obtained when packaging plasmids with complete packaging sites. Preferred cell lines package the plasmid V653gpt with a titer of  $10^4$  to about  $10^5$  transducing units per ml or more, more preferably at least about  $10^4$  to about  $10^6$  transducing units per ml or more, and most preferably at least about  $10^5$  transducing units per ml or more.

25 An HIV-1-MN clone is a clone derived from the publicly available HIV-1-MN genomic clone (Hall *et al.* (1992) *J. Virol* 66 (9) 5553-5560) by standard recombinant techniques such as subcloning, site-directed mutagenesis and the like, or, alternatively, an artificial nucleic acid synthesized based upon the HIV-1-MN genomic sequence. An example HIV-1-MN clone is the high efficiency  
30 packaging clone  $\Delta\Psi$  which is derived from the HIV-1-MN genomic sequence by deletion of the HIV-1 packaging site. Packaging vector nucleic acids of the

invention that are based on HIV-1MN have a deletion in the HIV packaging site, rendering the nucleic acid unpackageable by an HIV virus.

An "inhibitor" or "viral inhibitor" is most typically a nucleic acid which encodes an active anti-viral agent, or is itself an anti-viral agent. Thus, in one class of embodiments, the inhibitor is a "direct inhibitor," *i.e.*, the inhibitor acts directly on a viral component to inhibit the infection, replication, integration or growth of the virus in the cell. For instance, in one particularly preferred embodiment, the inhibitor comprises a *trans*-active ribozyme which cleaves an HIV transcript. In this configuration, the inhibitor is typically an RNA molecule with catalytic nuclease activity. In another class of embodiments, the inhibitor is an "indirect inhibitor," *i.e.*, the inhibitor *encodes* the direct inhibitor. An inhibitor "encodes" a direct inhibitor such as an active ribozyme, RNA molecular decoy, or anti-sense RNA if it contains *either* the sense or anti-sense coding or complementary nucleic acid which corresponds to the direct inhibitor. By convention, direct inhibitor RNAs such as ribozymes are typically listed as their corresponding DNA sequences. This is done to simplify visualization of the corresponding active RNA, which is equivalent to the given sequence with the T residues replaced by U residues.

"Viral inhibition" refers to the ability of a component to inhibit the infection, growth, integration, or replication of a virus in a cell. Inhibition is typically measured by monitoring changes in a cell's viral load (*i.e.*, the number of viruses and/or viral proteins or nucleic acids present in the cell, cell culture, or organism) or by monitoring resistance by a cell, cell culture, or organism to infection.

A "promoter" is an array of nucleic acid control sequences which direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements which can be located as much as several thousand base pairs from the start site of transcription.



A "constitutive" promoter is a promoter which is active under most environmental and developmental conditions. An "inducible" promoter is a promoter which is under environmental or developmental regulation.

The terms "isolated" or "biologically pure" refer to material which  
5 is substantially or essentially free from components which normally accompany it as found in its native state.

The term "heterologous" when used with reference to a nucleic acid indicates that the nucleic acid comprises two or more subsequences which are not found in the same relationship to each other in nature. For instance, the nucleic  
10 acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid. For example, in one embodiment, the nucleic acid has a promoter from one gene arranged to direct the expression of a coding sequence from a different gene. Thus, with reference to the coding sequence, the promoter is heterologous.

15 The term "identical" in the context of two nucleic acid or polypeptide sequences refers to the residues in the two sequences which are the same when aligned for maximum correspondence. When percentage of sequence identity is used in reference to proteins or peptides it is recognized that residue positions which are not identical often differ by conservative amino acid  
20 substitutions, where amino acids residues are substituted for other amino acid residues with similar chemical properties (*e.g.* charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution.  
25 Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution  
30 is given a score between zero and 1. The scoring of conservative substitutions is calculated, *e.g.*, according to the algorithm of Meyers and Miller, Computer

Applic. Biol. Sci., 4: 11-17 (1988) *e.g.*, as implemented in the program PC/GENE (Intelligenetics, Mountain View, California, USA).

A "comparison window", as used herein, refers to a segment of at least about 50 contiguous positions, usually about 50 to about 200, more usually  
5 about 100 to about 150 in which a sequence is compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison may be conducted by  
10 the local homology algorithm of Smith and Waterman (1981) *Adv. Appl. Math.* 2: 482; by the homology alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48: 443; by the search for similarity method of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85: 2444; by computerized implementations of these algorithms (including, but not limited to CLUSTAL in the PC/Gene program  
15 by Intelligenetics, Mountain View, California, GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wisconsin, USA); the CLUSTAL program is well described by Higgins and Sharp (1988) *Gene*, 73: 237-244 and Higgins and Sharp (1989) *CABIOS* 5: 151-153; Corpet, *et al.* (1988) *Nucleic Acids Research*  
20 16, 10881-90; Huang, *et al.* (1992) *Computer Applications in the Biosciences* 8, 155-65, and Pearson, *et al.* (1994) *Methods in Molecular Biology* 24, 307-31. Alignment is also often performed by inspection and manual alignment.

"Conservatively modified variations" of a particular nucleic acid sequence refers to those nucleic acids which encode identical or essentially identical  
25 amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given polypeptide. For instance, the codons CGU, CGC, CGA, CGG, AGA, and AGG all encode the amino acid arginine. Thus, at every position where an  
30 arginine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such

nucleic acid variations are "silent variations," which are one species of "conservatively modified variations." Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine) can be modified to yield a functionally identical molecule by standard techniques. Accordingly, each "silent variation" of a nucleic acid which encodes a polypeptide is implicit in any described sequence. Furthermore, one of skill will recognize that individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids (typically less than 5%, more typically less than 1%) in an encoded sequence are "conservatively modified variations" where the alterations result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

See also, Creighton (1984) *Proteins* W.H. Freeman and Company. Finally, the addition of sequences which do not alter the activity of a nucleic acid molecule, such as a non-functional sequence is a conservative modification of the basic nucleic acid.

"Stringent hybridization wash conditions" in the context of nucleic acid hybridization experiments such as Southern and northern hybridizations are sequence dependent, and are different under different environmental parameters. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) *Laboratory Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes* part I chapter 2 "overview of principles of hybridization and

the strategy of nucleic acid probe assays", Elsevier, New York. Generally, highly stringent hybridization and wash conditions are selected to be about 5° C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Very stringent conditions are selected to be equal to the  $T_m$  for a particular probe.

An example of stringent hybridization conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on a filter in a Southern or northern blot is 50% formalin with 1 mg of heparin at 42°C, with the hybridization being carried out overnight. An example of stringent wash conditions is a .2x SSC wash at 65°C for 15 minutes (*see, Sambrook, supra* for a description of SSC buffer). Often the high stringency wash is preceded by a low stringency wash to remove background probe signal. An example low stringency wash is 2x SSC at 40°C for 15 minutes. In general, a signal to noise ratio of 2x (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.

Nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, *e.g.*, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.

An "HIV-1 *gag* protein" is a protein encoded by the HIV-1 *gag* gene. The *gag* proteins are typically translated as a large preprotein which is cleaved to form the structural core proteins (*e.g.*, p17 and p24) which package wild-type HIV genomic RNA. A truncated *gag* protein is a protein produced from a *gag* protein with a deletion relative to the wild-type sequence.

The term "nucleic acid" refers to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, encompasses known analogues of natural nucleotides that hybridize to nucleic acids in manner similar to naturally occurring nucleotides.

Unless otherwise indicated, a particular nucleic acid sequence includes the complementary sequence thereof.

The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

The term "recombinant" when used with reference to a cell indicates that the cell replicates or expresses a nucleic acid, or expresses a peptide or protein encoded by nucleic acid whose origin is exogenous to the cell. Recombinant cells can express genes that are not found within the native (non-recombinant) form of the cell. Recombinant cells can also express genes found in the native form of the cell wherein the genes are re-introduced into the cell by artificial means.

A "recombinant expression cassette" or simply an "expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with nucleic acid elements which permit transcription of a particular nucleic acid in a cell. The recombinant expression cassette can be part of a plasmid, virus, or nucleic acid fragment. Typically, the recombinant expression cassette includes a nucleic acid to be transcribed, and a promoter. In some embodiments, the expression cassette also includes, *e.g.*, an origin of replication, and/or chromosome integration elements (*e.g.*, a retroviral LTR).

The term "subsequence" in the context of a particular nucleic acid sequence refers to a region of the nucleic acid equal to or smaller than the specified nucleic acid.

A virus or vector "transduces" a cell when it transfers nucleic acid into the cell. A cell is "transformed" by a nucleic acid when a nucleic acid transduced into the cell becomes stably replicated by the cell, either by incorporation of the nucleic acid into the cellular genome, or by episomal replication. A virus or vector is "infective" when it transduces a cell, replicates, and (without the benefit of any complementary virus or vector) spreads progeny vectors or viruses of the same type as the original transducing virus or vector to

other cells in an organism or cell culture, wherein the progeny vectors or viruses have the same ability to reproduce and spread throughout the organism or cell culture. Thus, for example, a nucleic acid encoding an HIV particles is *not* infective if the nucleic acid cannot be packaged by the HIV particle (*e.g.*, if the  
5 nucleic acid lacks an HIV packaging site), even though the nucleic acid can be used to transfect and transform a cell. Similarly, an HIV-packageable nucleic acid packaged by an HIV particle is *not* infective if it does not encode the HIV particle that it is packaged in, even though it may be used to transform and transfect a cell. If an HIV-packageable nucleic acid is used to transform a cell infected with HIV  
10 in a cell culture or organism infected with HIV, the HIV-packageable nucleic acid will be replicated and disseminated throughout the organism in concert with the infecting HIV virus. However, the HIV-packageable nucleic acid is *not* itself “infective”, because packaging functions are supplied by the infective HIV virus via trans complementation.

15 A cell “supernatant” is the culture medium in which a cell is grown. The culture medium includes material from the cell, including, *e.g.*, HIV viral particles which bud off from the cell membrane and enter the culture medium.

#### DETAILED DISCUSSION OF THE INVENTION

This invention provides HIV packaging cell lines, nucleic acids  
20 packaged by those cell lines and vectors comprising the packaged nucleic acids. In particular, this invention overcomes prior art deficiencies by providing well characterized HIV packaging cells with titers of  $10^4$  to  $10^6$  TU/ml. Furthermore, it is now discovered that such packaging cells are competent to package both HIV-1 and HIV-2 derived nucleic acids, *i.e.*, nucleic acids with either an HIV-1 or  
25 HIV-2 packaging site. Accordingly, one aspect of the invention provides an HIV-2 nucleic acid packaged in an HIV-1 based particle.

The packaging systems provided herein differ from prior art packaging systems in several respects. First, the packaging virions described so far have been derived from the HXBc2 plasmid. HXBc2 packaging virions are  
30 abnormal, with unprocessed p55<sup>Gag</sup> protein (Carroll, *et al.* (1994) *J. Virol.* 68(9):6047-6051), disproportionately low reverse transcriptase (RT) activity

(Carroll, *et al.* (1994) *J. Virol.* 68(9):6047-6051; Lever, *et al.* (1989) *J. Virol.* 63(9):4085-4087), and/or immature morphology revealed by electron microscopy (Aldovini, *et al.* (1990) *J. Virol.* 64(5):1920-1926; Clavel, *et al.* (1990) *J. Virol.* 64(10):5230-5234). It is now discovered that some of these deficiencies stem from  
5 the fact that HXBc2 lacks a full complement of the viral accessory genes, *e.g.* the *vpr* gene is truncated (Ratner, *et al.* (1987) *AIDS Res. Hum. Retroviruses* 3:57-69). Secondly, the packaging vectors used herein typically contain all of the RNA sequences that are involved in optimal HIV-1 packaging, whereas others have used vectors devoid of *gag* and/or *env* sequences. Third, in preferred embodiments,  
10 adherent Hela-T4 cells are used to titer g cell supernatants, rather than CD4<sup>+</sup> lymphoid T cells. The selection of untransduced cells is more efficient using adherent cells than using nonadherent cells, since the untransduced, dead cells are removed by washing, and toxicity is minimized. Fourth, the packaging cells are preferably stably transduced with a packaging vector *before* the packaging cells are  
15 transduced with a packageable nucleic acid, which reduces the likelihood for a recombination event leading to an infective virus. Fifth, the packaging cell lines of the invention include a packaging vector nucleic acid which encodes a functional *vpr* gene.

The establishment of stable cell lines producing high titers of fully  
20 characterized transducing particles is a major step forward in the utilization of HIV-derived constructs for gene therapy. One new class of vectors described herein comprise HIV-2 derived nucleic acids packaged in HIV-1 capsids. In addition to applications for therapy against HIV infection, the ability of HIV vectors to target CD4<sup>+</sup> lymphocytes as well as non-dividing cells such as cells of  
25 the monocyte/macrophages lineages, renders this vector/packaging system useful for targeting other hematopoietic disorders which are affected by CD4<sup>+</sup> cells. These include a number of T-cell lymphomas, HTLV-1 infection, Adult T cell leukemia, Myosis Fungoides and Segary's syndromes, CD4<sup>+</sup> lymphoblastic lymphomas, and peripheral CD4<sup>+</sup> T cell lymphomas. In addition, the invention,  
30 by providing a methods and compositions for transducing CD4<sup>+</sup> and CD34<sup>+</sup> cells in general, provides methods and compositions useful in general for the

transformation of cells, both *in vitro* and *in vivo*. Thus, the invention is useful as a general laboratory technique for the transformation of cells in cloning procedures.

## 5 Making Packaging Vectors and Packageable Nucleic Acids

The present invention provides a variety of packaging vectors and packageable nucleic acids as described *supra*. Packaging vectors include HIV-derived nucleic acids, particularly those derived from HIV-1-MN. Packageable nucleic acids encode RNAs which comprise an HIV packaging site (HIV-1 or HIV-  
10 2 derived), and optionally comprise other HIV-based nucleic acids, or heterologous nucleic acids. In particularly preferred embodiments, the packageable nucleic acids comprise HIV-2 components, including HIV-2 LTRs and packaging sites. One aspect of the invention is the discovery that the HIV-2 packaging site is packaged by the HIV-1 packaging machinery into HIV-1 particles.

15 The packaging vectors of the invention are derived from HIV-1 clones. Many such clones are known to persons of skill, and publicly available. Well-established repositories of sequence information include GenBank, EMBL, DDBJ and the NCBI. Well characterized HIV clones include HIV-1-MN and HIV-1-MN-ST.1 (Hall *et al.* (1992) *J. Virol* 66 (9) 5553-5560).

20 Furthermore, viral clones can be isolated from wild-type HIV viruses using known techniques. Typically, a lambda-phage clone, containing a full-length HIV provirus, is obtained from the genomic DNA of a lymphoblastic cell line infected with an HIV strain isolated from the peripheral blood mononuclear cells of an HIV seropositive AIDS patient. The virus is replication  
25 competent *in vitro*, producing p24 protein and infectious progeny virions after direct transfection into CD4<sup>+</sup> cells. Appropriate cells for testing infectivity include well characterized established human T-cells such as Molt-4/8 cells, SupT1 cells, H9 cells, C8166 cells and myelomonocytic (U937) cells as well as primary human lymphocytes, and primary human monocyte-macrophage cultures. In general, a  
30 complete virulent HIV viral genome can be used to make a packaging vector. A "full-length HIV genome" in relation to an HIV-1 packaging vector consists of a



nucleic acid (RNA or DNA) encoded by an HIV virus or viral clone which includes the 5' and 3' LTR regions and the genes between the LTR regions which are present in a typical wild-type HIV-1 virus (*e.g.*, *env*, *nef*, *rev*, *vpx*, *tat*, *gag*, *pol*, *vif*, and *vpr*).

5           The packaging vector is made by deleting the HIV packaging site from a full-length HIV genome. Specific mutations in the HIV packaging site are described, *e.g.*, in Aldovini and Young (1990) *Journal of Virology* 64(5):1920-1926. The RNA secondary structure of the packaging site is described in Clever *et al.* (1995) *Journal of Virology* 69(4): 2101-2109. The stem loops of the psi site  
10 for HIV-1 are described in Clever. In the packaging vectors of the invention, at least two of the four stem loops are deleted or substantially mutated to prevent loop formation. Preferably, three loops are deleted or mutated, and more preferably all four loops are deleted or mutated.

          In the packaging vectors of the invention, nucleic acids  
15 corresponding to at least two, and preferably three or all of the four stem loops of the  $\Psi$  structure are typically deleted from a clone of an HIV-1 viral genome. This results in substantial deletion in the region between the major splice donor site ("MSD") and the beginning of the *gag* gene. For instance, the  $\Delta\Psi$  plasmid described herein has a 37 base-pair deletion between the MSD and the beginning  
20 of the *gag* gene. Prior art deletion clone packaging vectors typically did not delete as large a portion of the packaging site, which resulted in partially infective packaging vectors (*i.e.*, attenuated, but still infective forms of HIV, which are unsuitable for use in packaging cells, and in producing high titers of packaged HIV-packageable nucleic acids, due to the risk of infection by the attenuated virus).

25

          The resulting deletion clones of the invention can be used to make viral particles, by transducing the deletion clone into a packaging cell (typically a Hela or other well-characterized cell) and expressing the clone. Because the clones lack the HIV packaging site, they are not packaged into the viral particles.

30           To increase the safety of the transduced packaging cells, it is preferable to cut (*e.g.*, by subcloning) the deletion clone (or homologous clones)

into multiple expression clones with complementary functions. This decreases the chances that a recombination event will result in an infectious particle.

Packageable nucleic acids encode an RNA which is competent to be packaged by an HIV particle. Such nucleic acids can be constructed by recombining an HIV packaging site with a nucleic acid of choice. The packaging site (psi site) is located adjacent to the 5' LTR, primarily between the MSD site and the *gag* initiator codon (AUG) in the leader sequence of the *gag* gene. Thus, the minimal HIV-1 packaging site includes a majority of nucleic acids between the MSD and the *gag* initiator codon from either HIV-1 or HIV-2. See also, Clever *et al.*, *supra* and Garzino-Demo *et al.* (1995) *Hum. Gene Ther.* 6(2): 177-184. For a general description of the structural elements of the HIV genome, see, Holmes *et al.* PCT/EP92/02787. Preferably, a complete packaging site includes sequences from the 5' LTR and the 5' region of *gag* gene for maximal packaging efficiency. These packaging sequences typically include a portion of the *gag* gene, *e.g.*, extending about 100 bases into the coding region of *gag* or further, and about 100 bases into the HIV 5' LTR or further. More preferably, the first 100-700 nucleotides from the *gag* gene are included. Yet more preferably, the first 500-660 nucleotides of *gag* are included. Most preferably, about the first 650 nucleotides of *gag* are included. In one well characterized embodiment (see, example 2) the first 653 nucleotides of *gag* are included. Alternatively, the vector VOGpt, described *supra*, includes a minimal HIV packaging site in conjunction with HIV LTRs, and is shown to be packageable by the cells of the invention. In addition, sequences from the *env* gene are preferably included in the packaging site, particularly the RRE. An example preferred packaging site is the packaging site from V653gpt described herein.

When an HIV-2 packaging site is used, the first ATG of *gag* to the MSD is preferably included as the HIV-2 packaging site. Still more preferably, the first 30 nucleotides of *gag* are also included as part of the HIV-2 packaging site. Typically, the first 50 nucleotides of *gag* are also included as part of the HIV-2 packaging site. Often the first 75 nucleotides of *gag* are also included as

part of the HIV-2 packaging site. Generally, the first 100 nucleotides of *gag* are also included as part of the HIV-2 packaging site.

Given the strategy for making the packaging and target packageable nucleic acids of the present invention, one of skill can construct a variety of clones  
5 containing functionally equivalent nucleic acids. Cloning methodologies to accomplish these ends, and sequencing methods to verify the sequence of nucleic acids are well known in the art. Examples of appropriate cloning and sequencing techniques, and instructions sufficient to direct persons of skill through many cloning exercises are found in Berger and Kimmel, *Guide to Molecular Cloning*  
10 *Techniques, Methods in Enzymology* volume 152 Academic Press, Inc., San Diego, CA (Berger); Sambrook *et al.* (1989) *Molecular Cloning - A Laboratory Manual* (2nd ed.) Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, NY, (Sambrook); and *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, eds., Current Protocols, a joint venture between Greene Publishing Associates,  
15 Inc. and John Wiley & Sons, Inc., (1994 Supplement) (Ausubel). Product information from manufacturers of biological reagents and experimental equipment also provide information useful in known biological methods. Such manufacturers include the SIGMA chemical company (Saint Louis, MO), R&D systems (Minneapolis, MN), Pharmacia LKB Biotechnology (Piscataway, NJ),  
20 CLONTECH Laboratories, Inc. (Palo Alto, CA), Chem Genes Corp., Aldrich Chemical Company (Milwaukee, WI), Glen Research, Inc., GIBCO BRL Life Technologies, Inc. (Gaithersburg, MD), Fluka Chemica-Biochemika Analytika (Fluka Chemie AG, Buchs, Switzerland), Invitrogen, San Diego, CA, and Applied Biosystems (Foster City, CA), as well as many other commercial sources known  
25 to one of skill.

The nucleic acid compositions of this invention, whether RNA, cDNA, genomic DNA, or a hybrid of the various combinations, are isolated from biological sources or synthesized *in vitro*. The nucleic acids of the invention are present in transformed or transfected whole cells, in transformed or transfected cell  
30 lysates, or in a partially purified or substantially pure form.

*In vitro* amplification techniques suitable for amplifying sequences for use as molecular probes or generating nucleic acid fragments for subsequent subcloning are known. Examples of techniques sufficient to direct persons of skill through such *in vitro* amplification methods, including the polymerase chain reaction (PCR) the ligase chain reaction (LCR), Q $\beta$ -replicase amplification and other RNA polymerase mediated techniques (*e.g.*, NASBA) are found in Berger, Sambrook, and Ausubel, as well as Mullis *et al.*, (1987) U.S. Patent No. 4,683,202; *PCR Protocols A Guide to Methods and Applications* (Innis *et al.* eds) Academic Press Inc. San Diego, CA (1990) (Innis); Arnheim & Levinson (October 1, 1990) *C&EN* 36-47; *The Journal Of NIH Research* (1991) 3, 81-94; (Kwoh *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86, 1173; Guatelli *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87, 1874; Lomell *et al.* (1989) *J. Clin. Chem* 35, 1826; Landegren *et al.*, (1988) *Science* 241, 1077-1080; Van Brunt (1990) *Biotechnology* 8, 291-294; Wu and Wallace, (1989) *Gene* 4, 560; Barringer *et al.* (1990) *Gene* 89, 117, and Sooknanan and Malek (1995) *Biotechnology* 13: 563-564. Improved methods of cloning *in vitro* amplified nucleic acids are described in Wallace *et al.*, U.S. Pat. No. 5,426,039.

Oligonucleotides for use as probes, *e.g.*, in *in vitro* amplification methods, for use as gene probes, or as inhibitor components (*e.g.*, ribozymes) are typically synthesized chemically according to the solid phase phosphoramidite triester method described by Beaucage and Caruthers (1981), *Tetrahedron Letts.*, 22(20):1859-1862, *e.g.*, using an automated synthesizer, as described in Needham-VanDevanter *et al.* (1984) *Nucleic Acids Res.*, 12:6159-6168. Oligonucleotides can also be custom made and ordered from a variety of commercial sources known to persons of skill. Purification of oligonucleotides, where necessary, is typically performed by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson and Regnier (1983) *J. Chrom.* 255:137-149. The sequence of the synthetic oligonucleotides can be verified using the chemical degradation method of Maxam and Gilbert (1980) in Grossman and Moldave (eds.) Academic Press, New York, *Methods in Enzymology* 65:499-560.

### Making Conservative Substitutions

One of skill will appreciate that many conservative variations of the nucleic acid constructs disclosed yield a functionally identical construct. For example, due to the degeneracy of the genetic code, "silent substitutions" (*i.e.*,  
5 substitutions of a nucleic acid sequence which do not result in an alteration in an encoded polypeptide) are an implied feature of *every* nucleic acid sequence which encodes an amino acid. Similarly, "conservative amino acid substitutions," in one or a few amino acids in an amino acid sequence of a packaging or packageable construct are substituted with different amino acids with highly similar properties  
10 (*see*, the definitions section, *supra*), are also readily identified as being highly similar to a disclosed construct. Such conservatively substituted variations of each explicitly disclosed sequence are a feature of the present invention.

One of skill will recognize many ways of generating alterations in a given nucleic acid construct. Such well-known methods include site-directed  
15 mutagenesis, PCR amplification using degenerate oligonucleotides, exposure of cells containing the nucleic acid to mutagenic agents or radiation, chemical synthesis of a desired oligonucleotide (*e.g.*, in conjunction with ligation and/or cloning to generate large nucleic acids) and other well-known techniques. *See*, Gilman and Smith (1979) *Gene* 8:81-97, Roberts *et al.* (1987) *Nature* 328:731-734  
20 and Sambrook, Innis, Ausbel, Berger, Needham VanDevanter and Mullis (*all supra*).

One of skill can select a desired nucleic acid of the invention based upon the sequences provided and upon knowledge in the art regarding HIV generally. The life-cycle, genomic organization, developmental regulation and  
25 associated molecular biology of HIV viruses have been the focus of over a decade of intense research. The specific effects of many mutations in the HIV genome are known. Moreover, general knowledge regarding the nature of proteins and nucleic acids allows one of skill to select appropriate sequences with activity similar or equivalent to the nucleic acids and polypeptides disclosed in the sequence listings  
30 herein. The definitions section herein describes exemplar conservative amino acid substitutions.

Finally, most modifications to nucleic acids are evaluated by routine screening techniques in suitable assays for the desired characteristic. For instance, changes in the immunological character of encoded polypeptides can be detected by an appropriate immunological assay. Modifications of other properties such as nucleic acid hybridization to a complementary nucleic acid, redox or thermal stability of encoded proteins, hydrophobicity, susceptibility to proteolysis, or the tendency to aggregate are all assayed according to standard techniques.

#### Making Stable Packaging Cell Lines

Stable packaging cell lines are made by stably transforming a mammalian cell with a packaging vector. The transformation of mammalian cells is known in the art. Host cells are competent or rendered competent for transformation by various known means. There are several well-known methods of introducing DNA into animal cells. These include: calcium phosphate precipitation, fusion of the recipient cells with bacterial protoplasts containing the DNA, treatment of the recipient cells with liposomes containing the DNA, DEAE dextran, receptor-mediated endocytosis, electroporation and micro-injection of the DNA directly into the cells.

The culture of cells used in conjunction with the present invention, including cell lines and cultured cells from tissue or blood samples is well known in the art. Freshney (*Culture of Animal Cells, a Manual of Basic Technique, third edition* Wiley-Liss, New York (1994)) and the references cited therein provides a general guide to the culture of cells. Transformed cells are cultured by means well known in the art. See, also Kuchler *et al.* (1977) *Biochemical Methods in Cell Culture and Virology*, Kuchler, R.J., Dowden, Hutchinson and Ross, Inc. Mammalian cell systems often will be in the form of monolayers of cells, although mammalian cell suspensions are also used. Illustrative examples of mammalian cell lines include VERO and Hela cells, Chinese hamster ovary (CHO) cell lines, W138, BHK, Cos-7 or MDCK cell lines (see, *e.g.*, Freshney, *supra*).

Supernatants from cell cultures of the packaging cells of the invention are obtained using standard techniques such as those taught in Freshney,

*supra*. See also, Corbeau *et al.* (1996) *Proc. Natl. Acad. Sci. USA* 93:14070-14075 and the references therein. Components from the cell supernatants can be further purified using standard techniques. For example, HIV particles in the supernatant can be purified from the supernatant by methods typically used for  
5 viral purification such as centrifugation, chromatography, affinity purification procedures, and the like.

Transforming mammalian cells with nucleic acids can involve, for example, incubating competent cells with a plasmid containing nucleic acids which code for an HIV particle. The plasmid which is used to transform the host cell  
10 preferably contains nucleic acid sequences to initiate transcription and sequences to control the translation of the encoded sequences. These sequences are referred to generally as expression control sequences. Illustrative mammalian expression control sequences are obtained from the SV-40 promoter (*Science* (1983) 222:524-527), the CMV I.E. Promoter (*Proc. Natl. Acad. Sci.* (1984) 81:659-663)  
15 or the metallothionein promoter (*Nature* (1982) 296:39-42). A cloning vector containing expression control sequences is cleaved using restriction enzymes and adjusted in size as necessary or desirable and ligated with DNA coding for the HIV sequences of interest by means well known in the art.

Polyadenylation or transcription terminator sequences from known  
20 mammalian genes are typically incorporated into the vector. An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript may also be included. An example of a splicing sequence is the VPI intron from SV40 (Sprague *et al.* (1983) *J. Virol.* 45: 773-781). Additionally, gene sequences to  
25 control replication in a particular host cell are incorporated into the vector such as those found in bovine papilloma virus type-vectors. See, Saveria-Campo (1985), "Bovine Papilloma virus DNA a Eukaryotic Cloning Vector" in *DNA Cloning Vol. II a Practical Approach* Glover (ed) IRL Press, Arlington, Virginia pp. 213-238.

Co-plasmids can be used in selection methods. In these methods,  
30 a plasmid containing a selectable marker, such as an antibiotic resistance gene, is used to co-transfect a cell in conjunction with a plasmid encoding HIV packaging

nucleic acids. The cells are selected for antibiotic resistance, and the presence of the plasmid of interest is confirmed by Southern analysis, northern analysis, or PCR. Co-plasmids encoding proteins to be expressed on the surface of an HIV particle (*e.g.*, proteins which expand the host range of the capsid such as the VSV envelope, a cell receptor ligand, or an antibody to a cell receptor) are optionally transduced into the packaging cell. In addition to VSV, the envelope proteins of other lipid enveloped viruses are optionally incorporated into a particle of the invention, thereby expanding the transduction range of the particle.

Viral vectors (*e.g.*, retroviral or adeno-associated viral vectors) containing nucleic acids which encode HIV sequences are also used to transform cells within the host range of the vector. See, *e.g.*, *Methods in Enzymology*, vol. 185, Academic Press, Inc., San Diego, CA (D.V. Goeddel, ed.) (1990) or M. Krieger, *Gene Transfer and Expression -- A Laboratory Manual*, Stockton Press, New York, NY, (1990) and the references cited therein.

Once stable transformed cell lines are made which express HIV particles, the transformed cell lines are transfected with vectors which encode nucleic acids to be incorporated into the HIV vectors. Typically, these vectors are plasmids or are coded in viral vectors. The packaged nucleic acids include an HIV packaging site subsequence in conjunction with a sequence of interest, such as a viral inhibitor or other gene therapeutic.

Hela cells are preferred packaging cell lines, and can be made competent for transformation by the techniques described above. For example, to generate a stable HIV-1 packaging cell line, Hela cells were transfected by the Calcium-Phosphate method. A subconfluent Hela culture in a 6-well plate (Costar, Cambridge, MA) was transfected with linearized and Calcium-Phosphate precipitated plasmid  $\Delta\psi$  (10 $\mu$ g) and plasmid SV-NEO containing the *neo'* gene driven by the SV40 promoter (0.6 $\mu$ g) in Dulbecco's modified Eagle's medium supplemented with 10% FCS, antibiotics and glutamine (DMEM-10%FCS). After 18 hours, wells were washed with Dulbecco's phosphate-buffered saline (PBS) pH 7.8, incubated for 2 min. at 20°C with 15% glycerol solution in HEPES-buffered saline (50mM HEPES pH 7.1, 280mM NaCl, 1.5mM



Na<sub>2</sub>HPO<sub>4</sub>), washed twice with PBS and cultured in DMEM-10%FCS. At day 3, 500 $\mu$ g/ml G418 (Gibco BRL, Grand Island, NY) was added to the cell culture.  $\psi$ 422 cells were transfected with 10 $\mu$ g of V653gpt by the same method.

5    Assaying for HIV packaging vectors, packageable nucleic acids and HIV particles in Packaging cell Lines, Target Cells and Cell Lysates

          A wide variety of formats and labels are available and appropriate for detection of packaging vectors, packageable nucleic acids and HIV particles in packaging cells, target cells, patients and cell lysates. HIV antibodies, and the  
10    polypeptides and nucleic acids of the invention are detected and quantified by any of a number of means well known to those of skill in the art. These include analytic biochemical methods such as spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and  
15    the like, and various immunological methods such as fluid or gel precipitin reactions, immunodiffusion (single or double), immunoelectrophoresis, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, and the like. Several commercially available ELISA assays for the detection of HIV components are available, allowing one of skill to  
20    detect HIV particles, or HIV virus in a biological sample.

          The detection of nucleic acids proceeds by well known methods such as Southern analysis, northern analysis, gel electrophoresis, PCR, radiolabeling and scintillation counting, and affinity chromatography. Many assay formats are appropriate, including those reviewed in Tijssen (1993) *Laboratory Techniques in*  
25    *biochemistry and molecular biology--hybridization with nucleic acid probes* parts I and II, Elsevier, New York and Choo (ed) (1994) *Methods In Molecular Biology Volume 33- In Situ Hybridization Protocols* Humana Press Inc., New Jersey (see also, other books in the Methods in Molecular Biology series); see especially, Chapter 21 of Choo (id) "Detection of Virus Nucleic Acids by Radioactive and  
30    Nonisotopic *in Situ* Hybridization". A variety of automated solid-phase detection techniques are also appropriate. For instance, very large scale immobilized

polymer arrays (VLSIPS™) are used for the detection of nucleic acids. *See*, Tijssen (*supra*), Fodor *et al.* (1991) *Science*, 251: 767- 777 and Sheldon *et al.* (1993) *Clinical Chemistry* 39(4): 718-719. Finally, PCR is also routinely used to detect nucleic acids in biological samples (*see*, Innis, *supra* for a general description of PCR techniques).

In one preferred embodiment, antibodies are used to detect proteins expressed by the packaged vector, the packaging nucleic acid or to monitor circulating HIV levels in human blood, *e.g.*, to monitor the *in vivo* effect of a gene therapeutic agent coded by the packaged nucleic acids. In other embodiments, antibodies are co-expressed in the packaging cells to be incorporated into viral particles. Methods of producing polyclonal and monoclonal antibodies are known to those of skill in the art, and many anti-HIV antibodies are available. *See, e.g.*, Coligan (1991) *Current Protocols in Immunology* Wiley/Greene, NY; and Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press, NY; Stites *et al.* (eds.) *Basic and Clinical Immunology* (4th ed.) Lange Medical Publications, Los Altos, CA, and references cited therein; Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed.) Academic Press, New York, NY; and Kohler and Milstein (1975) *Nature* 256: 495-497. Other suitable techniques for antibody preparation include selection of libraries of recombinant antibodies in phage or similar vectors. *See*, Huse *et al.* (1989) *Science* 246: 1275-1281; and Ward, *et al.* (1989) *Nature* 341: 544-546. Specific monoclonal and polyclonal antibodies and antisera will usually bind with a  $K_D$  of at least about .1 mM, more usually at least about 1  $\mu$ M, preferably at least about .1  $\mu$ M or better, and most typically and preferably, .01  $\mu$ M or better.

Polypeptides encoded by the nucleic acids of the invention can be used to make antibodies for the detection of HIV particles using known techniques. Polypeptides of relatively short size can be synthesized in solution or on a solid support. *See, e.g.*, Merrifield (1963) *J. Am. Chem. Soc.* 85:2149-2154. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. *See, e.g.*, Stewart and Young (1984) *Solid Phase Peptide Synthesis*, 2d. ed., Pierce Chemical Co. Larger polypeptides can be synthesized

recombinantly in prokaryotes or in eukaryotes. See, e.g., Sambrook and Ausbel and Berger (all *supra*) for details concerning cloning and expressing polypeptides, e.g., in *E. coli*. Expression systems for expressing polypeptides are available using *E. coli*, *Bacillus sp.* (Palva, I. *et al.*, 1983, *Gene* 22:229-235; 5 Mosbach, K. *et al.*, *Nature*, 302:543-545) and *Salmonella*. *E. coli* systems are the most common, and best defined prokaryotic expression systems and are, therefore, preferred. Expression in yeast and other eukaryotic cells, including mammalian cells is also well known and appropriate. See, e.g., Sherman *et al.* (1982) *Methods in Yeast Genetics*, Cold Spring Harbor Laboratory. See, e.g., *Methods* 10 *in Enzymology*, vol. 185, Academic Press, Inc., San Diego, CA (D.V. Goeddel, ed.) (1990); M. Krieger, *Gene Transfer and Expression -- A Laboratory Manual*, Stockton Press, New York, NY, (1990) and the references cited therein; and, Scopes (1982) *Protein Purification: Principles and Practice* Springer-Verlag New York.

15 Frequently, polypeptides and their corresponding antibodies will be labeled by joining, either covalently or non covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionucleotides, enzymes, substrates, cofactors, inhibitors, 20 fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced. See, Cabilly, U.S. Patent No. 4,816,567; and Queen *et al.* (1989) *Proc. Nat'l Acad. Sci. USA* 86: 10029-10033.

25 The culture of cells used in conjunction with the present invention, including cell lines and cultured cells from tissue or blood samples is well known in the art. Freshney (*Culture of Animal Cells, a Manual of Basic Technique, third edition* Wiley-Liss, New York (1994)) and the references cited therein provides a general guide to the culture of cells.

Use of the Nucleic acids of the Invention as Molecular Probes

In addition to their utility in making HIV packaging cell lines, the non-infective packaging vectors of the invention can be used to detect wild-type HIV in biological samples using Southern or northern blot assays. In brief, the packaging vector is labeled, typically using a radio or bioluminescent label, and used to probe a northern or Southern blot of a sample suspected of containing HIV virus. The use of the packaging vector as a probe is safer than the use of an infective virus as a probe. The packaging vector is also more likely to detect a wild type virus than a smaller probe, because, unlike a small probe, the packaging vector probe has virtually the entire genome in common with a wild-type virus, making it improbable that the wild type virus could escape detection by mutation of the probe binding site.

Furthermore, the packaging vectors can be used as positive controls in essentially all known detection methods for the detection of HIV. In this embodiment, a packaging vector nucleic acid or encoded polypeptide is used as a positive control to establish that an HIV detection assay is functioning properly. For instance, oligonucleotides are used as primers in PCR reactions to detect HIV nucleic acids in biological samples such as human blood in clinical settings. The packaging vector, which comprises nucleic acid subsequences corresponding to the region to be amplified is used as an amplification templates in a separate reaction from a test sample such as human blood to determine that the PCR reagents and hybridization conditions are appropriate. Similarly, the polypeptides encoded by the packaging vector can be used to check ELISA reagents in assays for the detection of HIV expression products in biological samples.

Packageable nucleic acids can be used in the same fashion as molecular probes, *e.g.*, when they encode HIV components such as HIV packaging sites, HIV LTRs and the like.

Cellular Transformation and Gene Therapy

The present invention provides packageable nucleic acids for the transformation of cells *in vitro* and *in vivo*. These packageable nucleic acids are packaged in HIV-1 particles in the HIV packaging cell lines described herein. The nucleic acids are transfected into cells through the interaction of the HIV particle surrounding the nucleic acid and the HIV cellular receptor. As shown in the examples herein, HIV vectors have anti-HIV activity *per se*, even without the addition of specific anti-HIV genes such as anti-HIV ribozymes.

Cells which are transfected by HIV particles include CD4<sup>+</sup> cells, including T-cells such as Molt-4/8 cells, SupT1 cells, H9 cells, C8166 cells and myelomonocytic (U937) cells as well as primary human lymphocytes, and primary human monocyte-macrophage cultures, peripheral blood dendritic cells, follicular dendritic cells, epidermal Langerhans cells, megakaryocytes, microglia, astrocytes, oligodendroglia, CD8<sup>+</sup> cells, retinal cells, renal epithelial cells, cervical cells, rectal mucosa, trophoblastic cells, and cardiac myocytes (*see also*, Rosenberg and Fauci 1, *supra*). Thus, the packageable nucleic acids of the invention are generally useful as cellular transformation vectors.

In one particularly preferred class of embodiments, the packageable nucleic acids of the invention are used in cell transformation procedures for gene therapy. Gene therapy provides methods for combating chronic infectious diseases such as HIV, as well as non-infectious diseases such as cancer and birth defects such as enzyme deficiencies. Yu *et al.* (1994) *Gene Therapy* 1:13-26 and the references therein provides a general guide to gene therapy strategies for HIV infection. *See also*, Sodoski *et al.* PCT/US91/04335. One general limitation of common gene therapy vectors such as murine retroviruses is that they only infect actively dividing cells, and they are generally non-specific. The present invention provides several features that allow one of skill to generate powerful retroviral gene therapy vectors which specifically target CD4<sup>+</sup> cells *in vivo*, and which transform many cell types *in vitro*. CD4<sup>+</sup> cells, including non-dividing cells, are transduced by nucleic acids packaged in HIV particles. HIV particles also infect other cell-types *in vitro* which exhibit little or no CD4 expression, such as

peripheral blood dendritic cells, follicular dendritic cells, epidermal Langerhans cells, megakaryocytes, microglia, astrocytes, oligodendroglia, CD8<sup>+</sup> cells, retinal cells, renal epithelial cells, cervical cells, rectal mucosa, trophoblastic cells, and cardiac myocytes (*see*, Rosenberg and Fauci 1, *supra*). Thus, these cells can be  
5 targeted by the HIV particle-packaged nucleic acids of the invention in *ex vivo* gene therapy procedures (the infection of these cell types by HIV *in vivo*, however, is rare), or in drug discovery assays which require transformation of these cell types. Lists of CD4<sup>+</sup> and CD4<sup>-</sup> cell types which are infectible by HIV have been compiled (*see*, Rosenberg and Fauci 1 *supra*; Rosenberg and Fauci (1989) *Adv*  
10 *Immunol* 47:377-431; and Connor and Ho (1992) in *AIDS: etiology, diagnosis, treatment, and prevention*, third edition Hellman and Rosenberg (eds) Lippincott, Philadelphia). In addition, the vectors are optionally pseudotyped for transformation of stem cells.

#### *Pseudotyping The Packageable Vector*

15 Hematopoietic stem cells are particularly preferred targets for cell transformation in general, and for gene therapy (particularly anti-HIV gene therapy) in particular. Packageable vectors are made competent to transform CD34<sup>+</sup> cells by pseudotyping the vector. This is done by transducing the packaging cell line used to package the vector with a nucleic acid which encodes  
20 the vesicular stomatitis virus (VSV) envelope protein, which is expressed on the surface of the vector. VSV infects both dividing and non-dividing CD34<sup>+</sup> cells, and pseudotype vectors expressing VSV envelope proteins are competent to transduce these cells.

Similarly, viral or cellular proteins in general can be co-expressed  
25 to increase the host range of an HIV-based vector. Typically, a nucleic acid encoding a selected protein is coexpressed in an HIV packaging cell of the invention. Protein encoded by the nucleic acid is incorporated into the particle which packages an HIV-packageable nucleic acid, which buds off from the packaging cell membrane. If the protein is recognized by a cellular receptor on  
30 a target cell, the particle is transduced into the cell by receptor mediated endocytosis. Preferred proteins include viral (particularly retroviral) envelope or

coat proteins, cell receptor ligands, antibodies or antibody fragments which bind cell receptors on target cells, and the like.

### *Preferred Promoters*

A preferred class of embodiments utilizes an HIV LTR sequence as a promoter for the HIV packageable vector. These LTR sequences are trans-activated upon infection of a cell containing the LTR promoter by the infecting virus. LTR promoters, in addition to binding *tat* and *rev* are responsive to *cellular* cytokines (such as IL-2 and SP-1) which act to permit transcription of the HIV genome upon infection. Thus, in one embodiment, a therapeutic nucleic acid of choice is placed under the control of an LTR promoter, rendering the cells ordinarily most vulnerable to HIV infection resistant to infection. See, e.g., Poznansky *et al.* (1991) *Journal of Virology* 65(1): 532-536 for a description of the region flanking the 5' LTR's ability to package vector nucleic acids.

Constitutive promoters for directing expression of therapeutic nucleic acids are also preferred, particularly pol III promoters. Copending applications SN 08/245,742 (Wong-Staal *et al.*, see also PCT application PCT/US94/05700 (WO 94/26877) and Chatterjee *et al.* (*Science* (1992), 258: 1485-1488, hereinafter Chatterjee *et al.* 1) describe anti-sense inhibition of HIV-1 infectivity in target cells using viral vectors with a constitutive pol III expression cassette expressing anti-TAR RNA. Chatterjee *et al.* (PCT application PCT/US91/03440 (1991), hereinafter Chatterjee *et al.* 2) describe viral vectors, including AAV-based vectors which express antisense TAR sequences. Chatterjee and Wong (*Methods, A companion to Methods in Enzymology* (1993), 5: 51- 59) further describe viral vectors for the delivery of antisense RNA. Copending application SN 08/442,061, filed May 16, 1995 and the corresponding PCT publication WO 94/26877 (PCT/US94/05700) describes a variety of anti-HIV therapy genes, and gene therapy strategies generally, including the use of suicide genes, trans-dominant genes, ribozymes, anti-sense genes, and decoy genes in gene therapy vectors. Yu *et al.* (1994) *Gene Therapy* 1: 13-26 and the references cited therein provides a general guide to gene therapy strategies useful against HIV infection. Constitutive HIV-LTR promoters are also known and preferred, such as the HIV-2<sub>KR</sub> LTR

described in copending application SN 60/001,441.

### *Ex Vivo Transformation of Cells*

*Ex vivo* methods for inhibiting viral replication in a cell in an organism involve transducing the cell *ex vivo* with a therapeutic nucleic acid of this invention, and introducing the cell into the organism. The cells are typically CD4<sup>+</sup> cells such as CD4<sup>+</sup> T cells or macrophage isolated or cultured from a patient, or are stem cells. See, e.g., Freshney *et al.*, *supra* and the references cited therein for a discussion of how to isolate and culture cells from patients. Alternatively, the cells can be those stored in a cell bank (e.g., a blood bank). In one class of preferred embodiments, the packageable nucleic acid encodes an anti-viral therapeutic agent (e.g., suicide gene, trans-dominant gene, anti-HIV ribozyme, anti-sense gene, or decoy gene) which inhibits the growth or replication of an HIV virus, under the control of an activated or constitutive promoter. The cell transformation vector inhibits viral replication in any of those cells already infected with HIV virus, in addition to conferring a protective effect to cells which are not infected by HIV. In addition, in preferred embodiments, the vector is replicated and packaged into HIV capsids using the HIV replication machinery, thereby causing the anti-HIV therapeutic gene to propagate in conjunction with the replication of an HIV virus. Thus, an organism infected with HIV can be treated for the infection by transducing a population of its cells with a vector of the invention and introducing the transduced cells back into the organism as described herein. Thus, the present invention provides a method of protecting cells *in vitro*, *ex vivo* or *in vivo*, even when the cells are already infected with the virus against which protection is sought.

In one particularly preferred embodiment, stem cells (which are typically not CD4<sup>+</sup>) are used in *ex-vivo* procedures for cell transformation and gene therapy. The advantage to using stem cells is that they can be differentiated into other cell types *in vitro*, or can be introduced into a mammal (such as the donor of the cells) where they will engraft in the bone marrow. Methods for differentiating CD34<sup>+</sup> cells *in vitro* into clinically important immune cell types using cytokines such as GM-CSF, IFN- $\gamma$  and TNF- $\alpha$  are known (see, Inaba *et al.*



(1992) *J. Exp. Med.* 176, 1693-1702, and Szabolcs *et al.* (1995) 154: 5851-5861). Methods of pseudotyping HIV-based vectors so that they can transform stem cells are described above.

Stem cells are isolated for transduction and differentiation using known methods. For example, in mice, bone marrow cells are isolated by sacrificing the mouse and cutting the leg bones with a pair of scissors. Stem cells are isolated from bone marrow cells by panning the bone marrow cells with antibodies which bind unwanted cells, such as CD4<sup>+</sup> and CD8<sup>+</sup> (T cells), CD45<sup>+</sup> (panB cells), GR-1 (granulocytes), and Ia<sup>d</sup> (differentiated antigen presenting cells). For an example of this protocol see, Inaba *et al.* (1992) *J. Exp. Med.* 176, 1693-1702.

In humans, bone marrow aspirations from iliac crests are performed *e.g.*, under general anesthesia in the operating room. The bone marrow aspirations is approximately 1,000 ml in quantity and is collected from the posterior iliac bones and crests. If the total number of cells collected is  $< 2 \times 10^8/\text{kg}$ , a second aspiration using the sternum and anterior iliac crests in addition to posterior crests is performed. During the operation, two units of irradiated packed red cells are administered to replace the volume of marrow taken by the aspiration. Human hematopoietic progenitor and stem cells are characterized by the presence of a CD34 surface membrane antigen. This antigen is used for purification, *e.g.*, on affinity columns which bind CD34. After the bone marrow is harvested, the mononuclear cells are separated from the other components by means of ficol gradient centrifugation. This is performed by a semi-automated method using a cell separator (*e.g.*, a Baxter Fenwal CS3000+ or Terumo machine). The light density cells, composed mostly of mononuclear cells are collected and the cells are incubated in plastic flasks at 37°C for 1.5 hours. The adherent cells (monocytes, macrophages and B-Cells) are discarded. The non-adherent cells are then collected and incubated with a monoclonal anti-CD34 antibody (*e.g.*, the murine antibody 9C5) at 4°C for 30 minutes with gentle rotation. The final concentration for the anti-CD34 antibody is 10 µg/ml. After two washes, paramagnetic microspheres (Dyna Beads, supplied by Baxter Immunotherapy Group, Santa Ana, California)

coated with sheep antimouse IgG (Fc) antibody are added to the cell suspension at a ratio of 2 cells/bead. After a further incubation period of 30 minutes at 4°C, the rosetted cells with magnetic beads are collected with a magnet. Chymopapain (supplied by Baxter Immunotherapy Group, Santa Ana, California) at a final  
5 concentration of 200 U/ml is added to release the beads from the CD34+ cells. Alternatively, and preferably, an affinity column isolation procedure can be used which binds to CD34, or to antibodies bound to CD34 (*see*, the examples below). *See*, Ho *et al.* (1995) *Stem Cells* 13 (suppl. 3): 100-105. *See also*, Brenner (1993) *Journal of Hematotherapy* 2: 7-17.

10 In another embodiment, hematopoietic stem cells are isolated from fetal cord blood. Yu *et al.* (1995) *PNAS* 92: 699-703 describe a preferred method of transducing CD34+ cells from human fetal cord blood using retroviral vectors.

*Ex vivo transformation of T cells*

Rather than using stem cells, T cells are also used in preferred  
15 embodiments in *ex vivo* procedures. Several techniques are known for isolating T cells. In one method, Ficoll-Hypaque density gradient centrifugation is used to separate PBMC from red blood cells and neutrophils according to established procedures. Cells are washed with modified AIM-V (which consists of AIM-V (GIBCO) with 2 mM glutamine, 10 µg/ml gentamicin sulfate, 50 µg/ml  
20 streptomycin) supplemented with 1% fetal bovine serum (FBS). Enrichment for T cells is performed by negative or positive selection with appropriate monoclonal antibodies coupled to columns or magnetic beads according to standard techniques. An aliquot of cells is analyzed for desired cell surface phenotype (*e.g.*, CD4, CD8, CD3, CD14, *etc.*).

25 Cells are washed and resuspended at a concentration of  $5 \times 10^5$  cells per ml of AIM-V modified as above and containing 5% FBS and 100 U/ml recombinant IL-2 (rIL-2) (supplemented AIM-V). Where the cells are isolated from an HIV+ patient, 25 nM CD4-PE40 (a recombinant protein consisting of the HIV-1-binding CD4 domain linked to the translocation and ADP-ribosylation  
30 domains of Pseudomonas aeruginosa exotoxin A) is optionally added to the cell cultures for the remainder of the cell expansion to selectively remove HIV infected

cells from the culture. CD4-PE40 has been shown to inhibit p24 production in HIV-1-infected cell cultures and to selectively kill HIV-1-infected cells.

To stimulate proliferation, OKT3 monoclonal antibody (Ortho Diagnostics) is added to a concentration of 10 ng/ml and the cells are plated in 24 well plates with 0.5 ml per well. The cells are cultured at 37°C in a humidified incubator with 5% CO<sub>2</sub> for 48 hours. Media is aspirated from the cells and 1 ml of vector-containing supernatant (described below) supplemented with 5 µl/ml of protamine sulfate, 100 U/ml rIL-2, 100 U/ml penicillin, 0.25 µg/ml amphotericin B/ml and an additional 100 µg/ml streptomycin (25 nM CD4-PE40 can be added as described above).

The expression of surface markers facilitates identification and purification of T cells. Methods of identification and isolation of T cells include FACS, column chromatography, panning with magnetic beads, western blots, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and the like, and various immunological methods such as fluid or gel precipitin reactions, immunodiffusion (single or double), immunoelectrophoresis, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, and the like. For a review of immunological and immunoassay procedures in general, see Stites and Terr (eds.) 1991 *Basic and Clinical Immunology* (7th ed.) and Paul *supra*. For a discussion of how to make antibodies to selected antigens see, e.g. Coligan (1991) *Current Protocols in Immunology* Wiley/Greene, NY; and Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press, NY; Stites et al. (eds.) *Basic and Clinical Immunology* (4th ed.)

In addition to the *ex vivo* uses described above, the packaging cell lines of the invention and the HIV packageable nucleic acids of the invention are useful generally in cloning methods. Packageable nucleic acids are packaged in an HIV particle and used to transform an HIV-infectible cell (e.g., a CD4<sup>+</sup> cell) *in vitro* or *in vivo*. This provides one of skill with a technique for transforming cells with a nucleic acid of choice, e.g., in drug discovery assays, or as a tool in

the study of gene regulation.

*In Vivo Transformation*

HIV particles containing therapeutic nucleic acids can be administered directly to the organism for transduction of cells *in vivo*.

- 5 Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells. Packageable nucleic acids packaged in HIV particles are used to treat and prevent virally-mediated diseases such as AIDS in patients. The packaged nucleic acids are administered in any suitable manner, preferably with pharmaceutically acceptable carriers. Suitable
- 10 methods of administering such packaged nucleic acids in the context of the present invention to a patient are available, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.

- Pharmaceutically acceptable carriers are determined in part by the
- 15 particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention.

- Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the packaged nucleic acid suspended in
- 20 diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, tragacanth,
- 25 microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers. Lozenge forms can comprise the active ingredient in a flavor, usually
- 30 sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia

emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.

The packaged nucleic acids, alone or in combination with other suitable components, can be made into aerosol formulations (*i.e.*, they can be  
5 “nebulized”) to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

Suitable formulations for rectal administration include, for example, suppositories, which consist of the packaged nucleic acid with a suppository base.  
10 Suitable suppository bases include natural or synthetic triglycerides or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the packaged nucleic acid with a base, including, for example, liquid triglycerides, polyethylene glycols, and paraffin hydrocarbons.

Formulations suitable for parenteral administration, such as, for  
15 example, by intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can  
20 include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. Parenteral administration and intravenous administration are the preferred methods of administration. The formulations of packaged nucleic acid can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials. The packaged nucleic acids are not freeze-dried (lyophilized) because HIV  
25 particles are destroyed by lyophilization.

Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. Cells transduced by the packaged nucleic acid as described above in the context of *ex vivo* therapy can also be administered intravenously or parenterally as described above.

30 The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial therapeutic response in the

patient over time, or to inhibit infection by a pathogen. The dose will be determined by the efficacy of the particular vector employed and the condition of the patient, as well as the body weight or surface area of the patient to be treated. The size of the dose also will be determined by the existence, nature, and extent  
5 of any adverse side-effects that accompany the administration of a particular vector, or transduced cell type in a particular patient.

In determining the effective amount of the vector to be administered in the treatment or prophylaxis of virally-mediated diseases such as AIDS, the physician evaluates circulating plasma levels, vector toxicities, progression of the  
10 disease, and the production of anti-vector antibodies. In general, the dose equivalent of a naked nucleic acid from a vector is from about 1  $\mu\text{g}$  to 100  $\mu\text{g}$  for a typical 70 kilogram patient, and doses of vectors which include a retroviral particle are calculated to yield an equivalent amount of inhibitor nucleic acid.

In the practice of this invention, compositions can be administered,  
15 for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or intrathecally. The preferred method of administration will often be oral, rectal or intravenous, but the vectors can be applied in a suitable vehicle for the local and topical treatment of virally-mediated conditions. The vectors of this invention can supplement treatment of virally-mediated conditions by any  
20 known conventional therapy, including cytotoxic agents, nucleotide analogues and biologic response modifiers.

For administration, inhibitors and transduced cells of the present invention can be administered at a rate determined by the LD-50 of the inhibitor, vector, or transduced cell type, and the side-effects of the inhibitor, vector or cell  
25 type at various concentrations, as applied to the mass and overall health of the patient. Administration can be accomplished via single or divided doses.

Prior to infusion, blood samples are obtained and saved for analysis. Between  $1 \times 10^8$  and  $1 \times 10^{12}$  transduced cells are infused intravenously over 60-200 minutes. Vital signs and oxygen saturation by pulse oximetry are closely  
30 monitored. Blood samples are obtained 5 minutes and 1 hour following infusion and saved for subsequent analysis. Leukopheresis, transduction and reinfusion are

repeated every 2 to 3 months for a total of 4 to 6 treatments in a one year period. After the first treatment, infusions can be performed on a outpatient basis at the discretion of the clinician. If the reinfusion is given as an outpatient, the participant is monitored for at least 4, and preferably 8 hours following the  
5 therapy.

Transduced cells are prepared for reinfusion according to established methods. See, Abrahamsen *et al.* (1991) *J. Clin. Apheresis* 6:48-53; Carter *et al.* (1988) *J. Clin. Arpheresis* 4:113-117; Aebersold *et al.* (1988), *J. Immunol. Methods* 112: 1-7; Muul *et al.* (1987) *J. Immunol. Methods* 101:171-181 and  
10 Carter *et al.* (1987) *Transfusion* 27:362-365. After a period of about 2-4 weeks in culture, the cells should number between  $1 \times 10^8$  and  $1 \times 10^{12}$ . In this regard, the growth characteristics of cells vary from patient to patient and from cell type to cell type. About 72 hours prior to reinfusion of the transduced cells, an aliquot is taken for analysis of phenotype, and percentage of cells expressing the  
15 therapeutic agent.

If a patient undergoing infusion of a vector or transduced cell develops fevers, chills, or muscle aches, he/she receives the appropriate dose of aspirin, ibuprofen or acetaminophen. Patients who experience reactions to the infusion such as fever, muscle aches, and chills are premedicated 30 minutes prior  
20 to the future infusions with either aspirin, acetaminophen, or diphenhydramine. Meperidine is used for more severe chills and muscle aches that do not quickly respond to antipyretics and antihistamines. Cell infusion is slowed or discontinued depending upon the severity of the reaction.

#### *HIV Vectors*

25 The present application provides stable packaging systems for gene transfer using an HIV-1 packaging cell line and high titers of HIV-based vectors. HIV based vectors specifically deliver genes into CD4<sup>+</sup> T cells and non-dividing cells such as terminally differentiated macrophages. In addition, packaging of a therapeutic gene in an HIV core ensures its cellular entry through the same cell  
30 compartments as its target, and increases its efficiency. Optional inclusion of

portions of the RRE targeting element further aids in colocalization of a therapeutic vector and HIV target.

Besides these remarkable targeting abilities due to virion components, an HIV-derived gene delivery has other advantages linked to vector components (Figure 7). These advantages occur, *e.g.*, after transgene integration and during wild-type HIV infection of the transduced cell. The first of these advantages is that expression of vector LTR-driven antiviral genes can be restricted to HIV-infected cells through *tat* regulation. Once an HIV vector is activated by wild-type HIV regulatory proteins, vector RNA and genomic RNA competes for dimerization and for packaging. HIV vectors typically contain, upstream of the 5' splice donor site, a region named the dimer linkage structure (DLS) involved in dimerization of HIV RNA strands. In particular, the first loop of the main packaging signal is able to induce the formation of homo- or heterodimers through a "kissing-loop" interaction. Therefore, HIV vector RNA can dimerize with HIV genomic RNA so that vector/genomic RNA heterodimers are encapsidated in budding particles. Such hybrid virions are less infectious because of a block in strand transfers during reverse transcription and/or as a result of the production of defective recombinants. Thus, a vector DLS interferes with the replicative cycle of HIV in transduced cells. Moreover, by interacting with the HIV genomic RNA DLS, the vector DLS can colocalize both RNAs. This colocalization improves the cleavage efficiency of the viral RNA by an anti-HIV ribozymes (discussed *supra*) inserted in the vector. HIV vectors also contain the main packaging signal (*psi* site). Therefore, they compete with wild-type HIV genomic RNA for packaging into neosynthesized virions during productive infection of transduced cells. During infection of transduced cells, neosynthesized viral particles package vector RNA. This way, they carry and propagate the vector RNA to cells infected during the HIV infection cycle. In vivo, this is a major advantage for an HIV-derived system of gene transfer (Figure 7).

HIV vectors interfere with wild-type HIV infection through other mechanisms as well. HIV vectors can have a TAR and/or RRE decoy effect on wild-type *tat* and/or *rev*, and reduce the infection of transduced cells.



### *Viral Inhibitors*

As shown in the examples herein, HIV vectors have anti-HIV activity per se. For example, the regulatory and packaging elements common to such vectors act as molecular decoys for HIV regulatory proteins. For example,  
5 vectors comprising TAR sequences act as tat decoys, and vectors comprising RRE sequences act as Rev decoys. HIV packaging sites found in HIV-based vectors acts as a decoy for HIV packaging elements.

Specialized viral inhibitors are also typically encoded by the packaged nucleic acids of the invention. Thus, techniques applicable to the  
10 construction and maintenance of nucleic acids apply to the inhibitors of the present invention. Anti-viral agents which are optionally incorporated into the viral inhibitors of the invention include anti-sense genes, ribozymes, decoy genes, and transdominant nucleic acids.

An antisense nucleic acid is a nucleic acid that, upon expression,  
15 hybridizes to a particular RNA molecule, to a transcriptional promoter or to the sense strand of a gene. By hybridizing, the antisense nucleic acid interferes with the transcription of a complementary nucleic acid, the translation of an mRNA, or the function of a catalytic RNA. Antisense molecules useful in this invention include those that hybridize to viral gene transcripts. Two target sequences for  
20 antisense molecules are the first and second exons of the HIV genes *tat* and *rev*. Chatterjee and Wong, *supra*, and Marcus-Sekura (*Analytical Biochemistry* (1988) 172, 289-285) describe the use of anti-sense genes which block or modify gene expression.

A ribozyme is a catalytic RNA molecule that cleaves other RNA  
25 molecules having particular nucleic acid sequences. General methods for the construction of ribozymes, including hairpin ribozymes, hammerhead ribozymes, RNase P ribozymes (*i.e.*, ribozymes derived from the naturally occurring RNase P ribozyme from prokaryotes or eukaryotes) are known in the art. Castanotto *et al* (1994) *Advances in Pharmacology* 25: 289-317 provides an overview of  
30 ribozymes in general, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNase P, and axhead ribozymes. Ribozymes useful in this

invention include those that cleave viral transcripts, particularly HIV gene transcripts. Ojwang *et al.*, *Proc. Nat'l. Acad. Sci., U.S.A.*, 89:10802-06 (1992); Wong-Staal *et al.* (PCT/US94/05700); Ojwang *et al.* (1993) *Proc Natl Acad Sci USA* 90:6340-6344; Yamada *et al.* (1994) *Human Gene Therapy* 1:39-45; Leavitt  
5 *et al.* (1995) *Proc Natl Acad Sci USA* 92:699-703; Leavitt *et al.* (1994) *Human Gene Therapy* 5:1151-1120; Yamada *et al.* (1994) *Virology* 205:121-126, and Dropulic *et al.* (1992) *Journal of Virology* 66(3):1432-1441 provide an examples of HIV-1 specific hairpin and hammerhead ribozymes.

Briefly, two types of ribozymes that are particularly useful in this  
10 invention include the hairpin ribozyme and the hammerhead ribozyme. The hammerhead ribozyme (*see*, Rossie *et al.* (1991) *Pharmac. Ther.* 50:245-254; Forster and Symons (1987) *Cell* 48:211-220; Haseloff and Gerlach (1988) *Nature* 328:596-600; Walbot and Bruening (1988) *Nature* 334:196; Haseloff and Gerlach (1988) *Nature* 334:585; and Dropulic *et al* and Castanotto *et al.*, and the references  
15 cited therein, *supra*) and the hairpin ribozyme (*see, e.g.*, Hampel *et al.* (1990) *Nucl. Acids Res.* 18:299-304; Hempel *et al.*, (1990) European Patent Publication No. 0 360 257; U.S. Patent No. 5,254,678, issued October 19, 1993; Wong-Staal *et al.*, PCT/US94/05700; Ojwang *et al.* (1993) *Proc Natl Acad Sci USA* 90:6340-6344; Yamada *et al.* (1994) *Human Gene Therapy* 1:39-45; Leavitt *et al.*  
20 (1995) *Proc Natl Acad Sci USA* 92:699-703; Leavitt *et al.* (1994) *Human Gene Therapy* 5:1151-1120; and Yamada *et al.* (1994) *Virology* 205:121-126) are catalytic molecules having antisense and endoribonucleotidase activity. Intracellular expression of hammerhead ribozymes and a hairpin ribozymes directed against HIV RNA has been shown to confer significant resistance to HIV infection.  
25 These ribozymes are constructed to target a portion of the HIV genome, or nucleic acid encoded by the genome. Preferred target sites in HIV-1 include the U5 region, and the polymerase gene.

The typical sequence requirement for cleavage by a hairpin ribozyme is an RNA sequence consisting of NNNG/CN\*GUCNNNNNNNN (where N\*G is  
30 the cleavage site, and where N is any of G, U, C, or A). The sequence requirement at the cleavage site for the hammerhead ribozyme is an RNA sequence

consisting of NUX (where N is any of G, U, C, or A and X represents C, U or A). Accordingly, the same target within the hairpin leader sequence, GUC, is targetable by the hammerhead ribozyme. The additional nucleotides of the hammerhead ribozyme or hairpin ribozyme which mediate sequence specificity, are  
5 determined by the common target flanking nucleotides and the hammerhead and hairpin consensus sequences.

A decoy nucleic acid is a nucleic acid having a sequence recognized by a regulatory nucleic acid binding protein (*i.e.*, a transcription factor, cell trafficking factor, *etc.*). Upon expression, the transcription factor binds to the  
10 decoy nucleic acid, rather than to its natural target in the genome. Useful decoy nucleic acid sequences include any sequence to which a viral transcription factor binds. For instance, the TAR sequence, to which the tat protein binds, and the HIV RRE sequence (in particular the SL II sequence), to which the rev proteins binds are suitable sequences to use as decoy nucleic acids.

15 A transdominant nucleic acid is a nucleic acid which expresses a protein whose phenotype, when supplied by transcomplementation, will overcome the effect of the native form of the protein. For example, *tat* and *rev* can be mutated to retain the ability to bind to TAR and RRE, respectively, but to lack the proper regulatory function of those proteins. In particular, *rev* can be made  
20 transdominant by eliminating the leucine-rich domain close to the C terminus which is essential for proper normal regulation of transcription. Tat transdominant proteins can be generated by mutations in the RNA binding/nuclear localization domain. Reciprocal complementation of defective HIV molecular clones is described, *e.g.*, in Lori *et al.* (1992) *Journal of Virology* 66(9) 5553-5560.

25

## EXAMPLES

The following examples are provided by way of illustration only and not by way of limitation. Those of skill will readily recognize a variety of noncritical parameters which could be changed or modified to yield essentially similar results.

### Materials and Methods

The following materials and methods were used in the examples below.

- 10 Packaging plasmid construction. The HIV-1-MN-ST.1 genome (Lori, *et al.* (1992) *J. Virol.* 66(9):5553-5560) was cloned into the commercial PCR™ 11 vector (Invitrogen, San Diego, CA). To delete the major packaging site (Figure 1), the first 743 bases of the HIV-1-MN LTR (nucleotide numbering according to G. Myers *et al.*, Eds. (1992) Human Retroviruses and AIDS Los Alamos National
- 15 Laboratory, Los Alamos, New Mexico; a compilation and analysis of nucleic acid and amino acid sequences) were amplified by PCR introducing an *Ascl* restriction site at the 3' end of the PCR product by using the following oligomers: 5' TGGATGGGTAAATTTACTCCC; 3'GGCGCGCCTCACCAGTCGCCGCCCC. This PCR product was cloned in the PCR 11 vector which contains a unique *Apa*
- 20 I restriction site (plasmid pLTR, Figure 2). Then a gag-pol fragment (from nucleotide 1 in gag to nucleotide 360 in pol) was amplified, introducing an *Ascl* restriction site at the 5' end of the PCR fragment by using the following oligomers: 5' oligo: GGGGCGCGCCGAGAGAGATGGGGTGCGAGAGCGTCGG;
- 25 3' oligo: CTGATCATACTGTCTTACTTTG. The resulting PCR fragment containing a unique *Apal* restriction site was cloned into the PCR 11 vector (plasmid pGAG). Plasmids pLTR and pGAG were digested by *Ascl* and *Apal* and the *Ascl*-*Apal* fragment of pGAG, corresponding to the 1230 first bases of gag was inserted in the pLTR clone (plasmid pLTR/GAG). Thus, 37 bases, starting from
- 30 6 bases downstream the 5' major splice donor to 7 bases upstream of the beginning of gag (Figure 1), were deleted in the pLTR/GAG construct. Finally an *Apal*-*Apal*

fragment of the parental pMN clone corresponding to the viral genome downstream from the Apal site in gag was inserted in pLTR/GAG to generate the plasmid  $\Delta\psi$ .  
Packaged plasmid construction. The vector V653gpt (Figure 1) was obtained by replacement of the *neomycin phosphotransferase* (*neo'*) gene on the previously  
5 described V653RSN plasmid (Parolin, *et al.* (1994) *J. Virol.* 68(6):3888-3895) with the *xanthine-guanine phosphoribosyl transferase* (*gpt*) gene. The *gpt* gene was amplified by PCR introducing an XhoI site at the 5' end and a Sall site at the 3' end of the PCR product by using the following oligomers: 5'oligo: CCGCTCGAGATGAGCGAAAAATACATCGTC; 3'oligo: CGGTCGACTTAGCGGCCGCGACCGGAGATTGGCGGG. V653RSN was  
10 digested with Sall, which recognizes 2 sites in the sequences flanking the *neo'* gene, and ligated with the PCR product digested with XhoI and Sall.

RT activity assay. To measure viral Reverse Transcriptase (RT) activity, culture supernatant (0.50ml) was mixed with 0.24ml 30% polyethylene glycol and 20 $\mu$ l  
15 4M NaCl, and microcentrifuged at 14,000 rpm for 30 min. The pellet was resuspended in 10mM Tris-HCl pH 7.8, 100mM NaCl, 1mM EDTA, 0.1% Triton X100, and 40 $\mu$ l of a mixture containing 62.5mM Tris-HCl pH 7.8, 25mM MgCl<sub>2</sub>, 25mM KCl, 2.5mM dithiothreitol, 31.25 $\mu$ g/ml poly(rA)xoligo(dT) 12-18 (Pharmacia), 62.5 $\mu$ Ci/6.25nmole/ml of (<sup>3</sup>H)dTTP. After a one-hour incubation at  
20 37°C the mixture was spotted on DE81 paper (Whatman, Maidstone, UK), air-dried, washed three times with 5% sodium pyrophosphate and twice more with water, and air-dried again. Radioactivity was measured by a scintillation spectrometer (Beckman, Fullerton, CA).

RT-PCR assay. Before HIV RNA detection, cell culture supernatant was treated  
25 with DNase I (Boehringer Mannheim, Indianapolis, IN) for one hour (500 $\mu$ l containing 10U of enzyme and 50 $\mu$ l of 200mM TrisHCl (pH 8.3), 500mM KCl, 25mM MgCl<sub>2</sub>, 1mg/ml bovine serum albumin). Then 500 $\mu$ l of 6M guanidine thiocyanate, 50mM Tris-HCl, and 5 $\mu$ l of glass milk (GENECLEAN 11, B10101, Vista, CA) was added, and the mixture was rotated for 90 min. at 20°C. After 3  
30 washings, the RNA in the pellet was air-dried and eluted with 5 $\mu$ l of water for 3 min. at 50°C. To this 5 $\mu$ l of RNA, 2U of Tth DNA polymerase and 1 $\mu$ l of 10x

RT buffer (Boehringer), 0.8 $\mu$ g HIV gag oligonucleotide SK39, and 1 $\mu$ l of 2mM dNTP were added. The RNA in this mixture was then reverse transcribed (4.5 $\mu$ l of the mixture and 0.5 $\mu$ l of 9mM MnCl<sub>2</sub> incubated 20 min. at 65°C). As a control a reaction was run without MnCl<sub>2</sub> (4.5 $\mu$ l of the mixture and 0.5 $\mu$ l of water on ice -  
5 for 20 min.). Finally, for the PCR, 2 $\mu$ l of 10x PCR buffer (Boehringer), 2.5 $\mu$ l of 7.5mM EGTA, 12.5 $\mu$ l of H<sub>2</sub>O, 0.8 $\mu$ g HIV gag oligonucleotide SK38, and 2 $\mu$ l of 2mM dNTP were added. After 5 min. at 94°C, 30 cycles were performed: denaturation for 1 min. at 94°C, hybridization for 1 min. at 52°C, and polymerization for 30 seconds at 72°C. The amplified products were run in a 2%  
10 agarose gel, blotted onto a GENESCREENPLUS nylon membrane (NEN Research Products, Boston, MA) by salt transfer, and hybridized with an  $\alpha$ -32P-labeled (RANDOM PRIMED DNA LABELING kit, Boehringer) HIV-1 gag fragment. Labeled RT-PCR fragments were visualized by autoradiography.

Infectivity assay. To determine the infectivity of HIV-1 virions, serial  
15 dilutions of culture supernatants were incubated in quadruplicate with 4x10<sup>4</sup> Molt4/8 cells in 200 $\mu$ l RPMI-10%FCS, cultured for 13 days, washed, and then cultured for an additional day. The percentage of cultures positive for HIV-1 p24 assay was then determined for each viral input.

Transduction. g cell (cells expressing an HIV packageable RNA) supernatants  
20 were filtered (pore size 0.22 $\mu$ m), diluted 1:10, and added for 24 hours to 30% confluent Hela T4 cells cultivated in 1ml DMEM-10%FCS (6-well plate, Costar). Two days later, the HelaT4 cells were selected in DMEM supplemented with 10% dialyzed FCS, 250 $\mu$ g/ml xanthine, 15 $\mu$ g/ml hypoxanthine, 10 $\mu$ g/ml thymidine, 2 $\mu$ g/ml aminopterin, 25 $\mu$ g/ml mycophenolic acid, and 150 $\mu$ g/ml of L-glutamine.  
25 After 4 weeks, resistant cells were counted under an inverted optical microscope.

PCR detection of the transduced vector. Genomic DNA was extracted using the QIAAMP BLOOD kit (QIAGEN, Chatsworth, CA). PCR was performed on 200ng DNA of transduced HelaT4 cells or  $\psi$ 422 cells (negative control), or on 2pg of V653gpt plasmid mixed with 200ng DNA of HelaT4 cells (positive  
30 control). A first LTR-RRE fragment of the vector was amplified using the following oligomers:

5'oligo: TTTTCGCGAGCGGCCGCCGGAAGGGCTAATTCCTCC, 3'oligo: GGTATCTTTCCACAGCTAGG; a second RRE-gpt fragment using the oligomers:

5'oligo: GGAGCTTTGTTCTTGGG, 3' oligo: ATCAACCAGCGGACGACCAG; and a third gpt-LTR fragment using the  
 5 oligomers: 5'oligo: AGCTACGATCACGACAACCA, 3' oligo: TTTTCGCGAGCGGCCGCTGCTAGAGATTTCACACTG. To 5 $\mu$ l of cellular DNA, 0.4 $\mu$ g of each oligomer, 2.5 $\mu$ l of 2mM dNTP, 2.5 $\mu$ l of 25mM MgCl<sub>2</sub>, 0.5U of Taq DNA polymerase and 2.5 $\mu$ l of 10x PCR buffer (Promega, Madison, WI), and water for a final volume of 25 $\mu$ l were added. After 5 min. at 94°C, 35 cycles  
 10 were performed: denaturation for 1 min. at 94°C, hybridization for 1 min. at 60°C, and polymerization for 2 min. 30 seconds at 72°C. The PCR fragments were then analyzed as described for the RT-PCR assay, the LTR-RRE and the gpt-LTR fragments being hybridized with an HIV-LTR probe, and the RRE-gpt fragment with a gpt probe.

15 RIPA. Ten million cells were washed with PBS, incubated one hour in cysteine-free DMEM-10%FCS, and then labelled for 5 hours by the addition of 10 $\mu$ l of L-<sup>35</sup>S cysteine (11mCi/0.0102 $\mu$ mol/ml). The cells were washed again with PBS and lysed in 2ml of 5mM Tris (pH 8.0), 150mM NaCl, 10mM EDTA, 0.1% SDS, 1mM PMSF, 1% TritonX100, 1% deoxycholic acid. After an one-hour  
 20 incubation at 4°C, the lysate was microcentrifuged for 30 min. at 14,000 rpm. One ml of supernatant was added to 6 $\mu$ g of protein A sepharose (CL-4B, Pharmacia LKB, Uppsala, Sweden) that had been preincubated with 10 $\mu$ l of a pool of human HIV+ plasma. After 18 hours of incubation at 4°C, the sepharose was washed, boiled for 10 min., and microcentrifuged. Twenty-five  $\mu$ l of the  
 25 supernatant was then run on an SDS-PAGE gel. After electrophoresis, the gel was dried and autoradiographed.

### Example 1: A Stable HIV-1 Packaging Cell Line

The HIV-1<sub>MN</sub>ST.1 molecular clone was chosen as the base clone for  
 30 making a packaging cell line because of its efficiency of infection in both monocytes and T-cells (Lori, *et al.* (1992) *J. Virol.* 66(9):5553-5560). The

packaging vector  $\Delta\psi$  was constructed by deleting 37 bases between the major splice donor site and the beginning of the *gag* gene (Figure 1), a sequence within the previously defined major packaging site for HIV-1 (Lever, *et al.* (1989) *J. Virol.* 63(9):4085-4087; Aldovini, *et al.* (1990) *J. Virol.* 64(5):1920-1926; Clavel, *et al.* (1990) *J. Virol.* 64(10):5230-5234; Poznansky, *et al.* (1991) *J. Virol.* 65:532-536; Hayashi, *et al.* (1992) *Virology* 188:590-599). For this deletion, PCR fragments derived from the LTR and *gag* were first ligated to each other, and then subsequently ligated with the rest of the viral genome to generate the  $\Delta\psi$  clone (see, Methods and Figure 2).  $\Delta\psi$  was used to generate an HIV-1 packaging line. For this purpose, HeLa cells were cotransfected with  $\Delta\psi$  and a plasmid containing the *neo'* gene and cultured in the presence of neomycin (G418).

The HeLa cells were transfected by the Calcium-Phosphate method. A subconfluent HeLa culture in a 6-well plate (Costar, Cambridge, MA) was transfected with linearized and Calcium-Phosphate precipitated plasmid  $\Delta\gamma$  (10 $\mu$ g) and plasmid SV-NEO containing the *neo'* gene driven by the SV40 promoter (0.6 $\mu$ g) in Dulbecco's modified Eagle's medium supplemented with 10% FCS, antibiotics and glutamine (DMEM-10%FCS). After 18 hours, wells were washed with Dulbecco's phosphate-buffered saline (PBS) pH 7.8, incubated for 2 min. at 20°C with 15% glycerol solution in HEPES-buffered saline (50mM HEPES pH 7.1, 280mM NaCl, 1.5mM Na<sub>2</sub>HPO<sub>4</sub>), washed twice with PBS and cultured in DMEM-10%FCS. At day 3, 500 $\mu$ g/ml G418 (Gibco BRL, Grand Island, NY) was added to the cell culture.

A G418-resistant clone,  $\psi$ 422, which produced 20ng/ml of p24<sup>Gag</sup> antigen, as measured in the culture supernatants using a commercial ELISA kit (Coulter, Miami, FL), was isolated and further analyzed. This clone was able to induce the formation of syncytia after an overnight coculture with uninfected CD4<sup>+</sup> human T-cells Molt4/8 (data not shown). To determine if HIV-1 structural proteins were correctly expressed in the  $\psi$ 422 cells, the cells were metabolically labeled and the viral proteins immunoprecipitated from the cell lysate.  $\psi$ 422 cells synthesize the major HIV-1 structural proteins, including the envelope precursor gp160 and the external envelope glycoprotein gp120, the p55 *gag* immature protein



and its p25 subproduct. Electron microscopy showed the production of a large amount of virions by the  $\psi$ 422 cell line, including many mature particles. These particles contain comparable specific RT activity (4,947cpm/50ng p24/ml) to that of wild type MN virions (5,364cpm/50ng p24/ml) (*see, methods*). However, these particles are not infectious, as shown in Figure 3. CD4<sup>+</sup> T-cells Molt4/8 exposed to the equivalent of 1 ng of p24 of  $\psi$ 422 virions did not express p24 antigen 14 days later. In the same experiment, HIV production was detected in cell cultures exposed to 10 pg of wild type HIV-1-MN virions. The lack of infectivity of the  $\psi$ 422 viral particles correlated with a reduction in the RNA content in these particles. Viral RNA was not detected by RT-PCR in 140pg of p24 equivalent of  $\psi$ 422 virions, whereas HIV RNA was detected in 35pg of p24 equivalent of wild type MN virions. The  $\psi$ 422 cell line has been stable in culture for several months, producing 1 to 20ng/ml p24 equivalent of non-infectious virions.

**Example 2: Use of  $\psi$ 422 cell line for gene transfer.**

In addition to the main  $\psi$  sequence encompassing the major splice donor site and the beginning of *gag*, other sequences within the HIV-1 genome play a role in the packaging of viral RNA. The first hundred bases of the *gag* gene is involved in the binding of the viral RNA to the nucleocapsid of the virion (Buchsacher, *et al.* (1992) *J. Virol.* 66(5):2731-2739; Parolin, *et al.* (1994) *J. Virol.* 68(6):3888-3895; Luban, *et al.* (1991) *J. Virol.* 65:3203-3212; Berkowitz, *et al.* (1993) *J. Virol.* 67(12):71 90-7200; Luban, *et al.* (1994) *J. Virol.* 68(6):3784-3793). A stretch within the *env* gene, including the Rev Responsive Element (RRE) has been reported to also contain a packaging signal (Richardson, *et al.* (1993) *J. Virol.* 67(7):3997-4005; Parolin, *et al.* (1994) *J. Virol.* 68(6):3888-3895). An HIV-1 vector, V653RSN, containing the first 653 bases of *gag* and an RRE-containing fragment of *env* is available (Parolin, *et al.* (1994) *J. Virol.* 68(6):3888-3895). The *neo*<sup>r</sup> gene in V653RSN was replaced with the *gpt* gene and transfected this new plasmid, V653gpt, into  $\psi$ 422 cells. *Gpt* can serve as a positive selectable marker in media containing mycophenolic acid, an inhibitor of *de novo* synthesis of guanine monophosphate (Mulligan, *et al.* (1981) *Proc.*

*Natl. Acad. Sci. USA.* 78(4):2072-2076). Moreover, *gpt* also serves as a negative selectable marker, a suicide gene, using 8-thioxanthine as a counter selective agent (Spring, *et al.* (1994) *Biochemica et Biophysica Acta.* 1218:158-162). Mycophenolic acid-resistant cell lines (g lines) were isolated from the transfected  $\psi$ 422 cells and their filtered supernatants were used to transduce Hela-T4 cells. Transduction efficiency was evaluated 4 weeks later by counting the mycophenolic acid-resistant Hela-T4 cells. After this selection almost all the Hela-T4 cells transduced with plain medium,  $\psi$ 422 cell supernatant or V653gpt transfected Hela cell supernatant were dead. In contrast, up to  $10^5$  resistant cells were obtained after transduction with 1ml of two g cell lines supernatants (Table 1). The capacity of these two g cell lines, gV and gZ, to transfer mycophenolic acid resistance was dependent on the presence of the CD4 receptor on target cells. Hela CD4<sup>-</sup> cells incubated with g cell supernatant died within 3 weeks in the presence of mycophenolic acid (Table 1).

15

TABLE 1: Transduction Capacity of g Cell Lines

Cell Supernatant	Target Cell	Experiment	Titer (Transducing units/ml)
gV	Hela-T4	1	$1.2 \times 10^4$
		2	$1.0 \times 10^4$
		3	$4.6 \times 10^4$
gZ	Hela		0
gZ	Hela-T4	1	$1.0 \times 10^4$
		2	$1.3 \times 10^4$
		3	$1.4 \times 10^5$
	Hela		0

Packaging vectors were examined to determine whether replication competent viruses could arise through recombination between viral sequences in the packaging cell line and the packaged nucleic acid. Infectivity of gV and gZ supernatants was tested on Molt4/8 cells. No trace of viral production was detected even when the culture was inoculated with the highest concentration of

25

virions produced by the g cells (Figure 3).

To determine if the transfer of the *neo'* gene was accomplished without rearrangement, the integrity of the V653gpt vector in the transduced cells was checked by PCR. Three overlapping fragments of the vector were amplified  
5 from DNA of transduced cells, blotted and hybridized with specific probes. PCR was also carried out on  $\psi$ 422 cells as a negative control, and on V653gpt plasmid as a positive control. The size and the specificity of the PCR products demonstrated that the V653gpt vector was transferred without modification.

### 10           **Example 3: Construction of an HIV-2 based gene delivery system**


Unlike most retroviruses, HIV is able to infect and replicate in non-dividing cells (*e.g.* monocytes) in the absence of DNA synthesis. Therefore, gene delivery with an HIV vector for HIV infection has a distinct advantage over standard murine retroviral vectors. Use of an HIV-derived vector is also desirable  
15 for gene therapy for HIV infection and AIDS, since the packaging signal in the vector RNA is recognized by HIV gag proteins in infected cells, with three primary consequences. First, the vector RNA competes with viral RNA for packaging. Second, the vector RNA is rescued and disseminated to a larger pool of potential HIV target cells. Expression of the inhibitory genes is at minimal  
20 levels in uninfected cells, alleviating concerns about cellular toxicity. Third, the presence of a packaging signal sequence in a therapeutic RNA transcript (*e.g.* a ribozyme or anti-sense RNA) allows tracking of the RNA with HIV RNA to the same cellular compartments, increasing efficiency of activity.

Human immunodeficiency virus type 2 (HIV-2)-based retroviral  
25 vectors have several desirable features as vehicles for gene therapy. For instance, the vectors have cell specificity, regulated expression, lower homology to HIV-1 than HIV-1 vectors (preventing homologous recombination to form pathogenic strains of HIV) and attenuated cytopathicity (the latency period for HIV-2 is typically about two to ten times that of HIV-1).

30           Packaging of HIV-2 vectors depends on efficient packaging of RNA into retroviral particles, which is mediated by a cis-acting sequence element called

the packaging signal or "psi" site ( $\psi$ ). For most retroviruses, including HIV-1 and HIV-2, the principal part of this element is located between the major splice donor site and the gag initiator codon (AUG) in the leader sequence. In the preferred vector of this example, the vector comprises HIV-2 long-terminal repeats (LTR) the HIV-2 psi-site and an internal pol II promoter driving a selectable marker gene. The HIV-2 based components are derived from HIV-2<sub>KR</sub> described in USSN 60/001,441 and on deposit with the ATCC 97234. The complete sequence of HIV-2<sub>KR</sub> is available from GenBank (Accession No. U22047. The HIV-2<sub>KR</sub> LTRs do not require Rev for basal transcription, and HIV-2<sub>KR</sub> exhibits reduced cytopathicity compared to other HIV viral clones.

To ensure Rev independence, the vectors had a 340 bp insert from the Mason Pfizer Monkey Virus (MPMV) inserted into the vector. The insert is sufficient to target nucleic acids to the cytosol in the absence of Rev. *See, Bray et al. (1994) Proc. Natl. Acad. Sci. USA 91: 1256-1260.* The Rev response element (RRE) was deleted.



Basic HIV-2 gene delivery vectors. IP indicates an internal promoter; the marker gene is neo or x-gpt. The 340 stands for the MPMV sequence.

The deletion of the RRE element has an advantage over earlier described HIV vector designs, because RRE expression has been shown to be cytotoxic over time in cells. This design allows for addition of optimum amounts of the gag sequence required for maximum packaging efficiency into the vector construct, because instability sequences (INS) (*See, Schwartz et al. (1992) Journal of Virology 66:7176-7182*) are overwritten by this specific MPMV sequence.

To avoid possible recombination events between the HIV-2 based


vector and an HIV-2 based packaging cell line, which can result in wild type HIV-2, the vector was packaged in the HIV-1 packaging cell line  $\psi$ -422 described above. The data below shows the rescueability by the HIV-1 packaging cell line, and demonstrates a packaging site decoy effect.

5

Table 2. Transduction capacity of HIV-2 based vector produced on  $\psi$ -422 packaging cell line.

Cell line	supernatant p24 (ng/ml)	Transduction capacity (Transducing particles/ml)
$\psi$ VR 3.4	1.2	3500
$\psi$ VW 4.5.6	1.8	2100

10



Rev and rre independent double copy vector. Stripes indicate the inserted pol III promoter and gene cassette.

60


Table 3

	Cell Supernatant	Target Cell	Experiment	Titer (TU/ml)
5	ψ422	Hela-T4		0
	VR-transfected Hela	Hela-T4		0
	VW-transfected Hela	Hela-T4		0
	ψVR	Hela-T4	1	0.4x10 <sup>4</sup>
		Hela-T4	2	1.0x10 <sup>4</sup>
		Hela-T4	3	2.1x10 <sup>4</sup>
		Hela		0
	ψVW	Hela-T4	1	0.1x10 <sup>4</sup>
		Hela-T4	2	2.1x10 <sup>4</sup>
		Hela-T4	3	1.0x10 <sup>4</sup>
		Hela		0

10 Further improvements to the HIV-2 gene delivery system were also made. A t-RNA<sup>Val</sup> pol III promoter was cloned into the U3 region of the 3'LTR for transcription of therapeutic genes such as Ribozymes, RNA-decoys and antisense-RNAs constructs. This design provides a "double copy vector," once the vector genome is reverse transcribed and integrated into the cellular genome. This

15 novel design provides increased RNA levels of the therapeutic genes.

61



Construction of the HIV-2 double copy vectors. pLTR plasmid was digested with Age I and the overhang was filled in. A t-RNA<sup>Val</sup>+Ribozyme cassette was inserted (*See*, WO 94/26877). The plasmid was digested with Cla I and the insert from the vector was cloned into the Cla I site.

This HIV-2-based retroviral vector provides targeted gene delivery and regulated expression of immunogens or antiviral agents in CD4<sup>+</sup> cells. Furthermore, it can be pseudo-typed by supplying *env* genes *in trans*, using the VSV G protein to make the vector able to infect stem cells.

5           **Example 4: Anti-HIV Effects of HIV based Vectors**

After stable transfection with an HIV-1 or HIV-2 vector,  $\psi$ 422 was shown to synthesize virions able to transduce CD4<sup>+</sup> T cells and macrophages, as shown, *supra*. It was also found that HIV vectors *per se*, in the absence of a particular antiviral gene, had inhibitory effects on  
10 HIV infection of transduced cells.

Using a CAT assay, an RNA transactivation responsive element (TAR) decoy effect of an HIV-1 vector on the viral *tat* transactivator was monitored, and the consequence of this inhibition evaluated on viral production. Moreover, another HIV-1 vector, which  
15 contained the *rev* responsive element (RRE), had an RRE-decoy effect on the wild type *rev* protein. These data highlight an advantage of HIV-derived gene delivery systems. Besides improving the targeting into HIV-infectible cells and non-dividing cells, HIV packaged HIV-based vectors have anti-HIV effects, *e.g.*, through interference of vector  
20 components with the HIV replicative cycle.

**Vectors.** The vector VOgpt (Figure 8, panel a) was generated from the VOSN plasmid (Parolin *et al.* (1994) *J. Virol.* 68(6):3888-3895) by replacing the *neomycin phosphotransferase* (*neo*<sup>R</sup>) gene with the *xanthine-guanine phosphoribosyl transferase* (*gpt*) gene. The *gpt* gene was  
25 amplified by PCR introducing XhoI and Sall sites at the 5' and 3' ends of the PCR product respectively using the oligomers:

5'    C C G C T C G A G A T G A G C G A A A A T A C A T C G T C ;  
3' C G G T C G A C T T A G C G G C C G C G A C C G G A G A T T G G C G G G .

VOSN was deleted of a Sall-Sall fragment containing the *neo*<sup>R</sup> gene, and ligated with  
30 the PCR product digested with XhoI and Sall. V653gpt is described *supra*.



Transfection of the packaging cell line with the HIV vector, infectivity test, transduction, southern blot on transduced cells. These assays were performed as described *supra* and in Corbeau *et al.* (1996) *Proc. Natl. Acad. Sci. USA* 93:14070-14075.

- 5 Plasmids used in CAT assay. As shown in Figure 8, pLTR-CAT and pCMV-CAT plasmids contain the *chloramphenicol acetyltransferase (CAT)* reporter gene driven by an HIV-1 LTR and a cytomegalovirus (CMV) promoter, respectively. In pTAT, the *tat* gene is driven by an HIV-1 LTR. pRSV-REV contains the Rous sarcoma virus promoter, and the *rev* gene  
10 from HIV-1-BRU. pDM128, derived from the *env* region of HIV-1, contains the Simian Virus 40 promoter, the *CAT* gene and a fragment of HIV-1 *env* including RRE, both in an intron flanked by HIV-1 splice donor and acceptor sites.

- CAT assays. Plasmids were transfected by electroporation at 12, 6, 12,  
15 12, and 6  $\mu\text{g/ml}$  for pLTR-CAT, pTAT, pCMV-CAT, pDM128, and pRSV-REV respectively. Four million Hela-T4 cells in 400  $\mu\text{l}$  of RPMI1640-20% were mixed at 4°C with the plasmids. After 10 min on ice, cells were electroporated at 250 V, and cultured in T25 flasks (Costar) containing 8 ml of DMEM-10%FCS. At day 3 post-electroporation,  
20 CAT production was determined by immunocapture on the cell lysate (CAT ELISA, Boehringer Mannheim, Indianapolis, IN). To determine the protein concentration, 8  $\mu\text{l}$  of each cell lysate was mixed in a microtiter plate with 152  $\mu\text{l}$  of water and 40  $\mu\text{l}$  of Bradford protein assay dye reagent concentrate (Bio-Rad, Hercules, CA), and the absorbance was read at 570  
25 nm. A standard curve was established using bovine immunoglobulins.

Cell transfection with HIV-1-MN. Cells were electroporated as described in the CAT assay, and the p24 production was monitored in the culture supernatant using an antigen capture assay (Coulter). The HIV-1-MN molecular clone has been described previously.

- 30 Anti-reverse effect of the V653gpt vector. The HIV-1 vector V653gpt was used to transduce CD4<sup>+</sup> cells. V653gpt contains the two HIV LTRs, a

SL3-gpt cassette containing the selectable marker gene *xanthine-guanine phosphoribosyl transferase* (*gpt*), driven by an internal promotor, the murine retroviral LTR SL3, and three sequences involved in packaging: the major  $\psi$  sequence, a 5' portion of the *gag* gene, and a fragment of the *env* gene. This *env* fragment encompasses RRE. During wild-type HIV infection of a V653gpt-transduced cell, vector RRE sequences could have a decoy effect on neosynthesized rev proteins. To test this possibility, a functional assay to assess Rev function was performed. This assay uses a reporter plasmid, pDM128, which contains RRE and the *CAT* gene in an intron (Figure 8, panel b). In the absence of rev, cells transfected with pDM128 express only cytoplasmic spliced transcripts and do not produce CAT protein. In the presence of rev, unspliced RNAs enter the cytoplasm, and CAT is synthesized. The amount of CAT produced by transduced or non-transduced cells was compared after cotransfection with the reporter gene, pDM128, and a plasmid encoding rev, pRSV-REV (Figure 8, panel b). In addition, the cells were also transfected with the tat expression plasmid, pTAT, to induce the expression of RRE<sup>+</sup> V653gpt transcripts. The rev-dependent production of the CAT molecule was reduced in V653gpt-transduced cells. To ensure that this impaired CAT production was not due to any constitutive defect of the V653gpt-transduced cells, a plasmid, pCMV-CAT, harboring the same reporter gene, *CAT*, but under the control of a CMV promoter was comparatively assessed. The expression of CAT after transfection with pCMV-CAT was similar in transduced and non-transduced Hela-T4 cells. Thus, V653gpt will interfere with the rev-RRE interaction necessary for viral constitutive proteins expression during HIV infection. It is noteworthy that for this vector, the RRE decoy expression is inducible, so that no toxic effect due to the sequestration of RRE-binding cellular factors is observed. Because of RRE, V653gpt will likely follow the rev-RRE export pathway from the nucleus to the cytoplasm, and thereby be localized with HIV RNA (Figure 7). Such a colocalization is an advantage for a vector carrying an antiviral agent

such as a ribozyme. Finally, V653gpt, which contains a 5'-fragment of the *gag* gene, which has additional anti-HIV effects. The truncated gag proteins it encodes associates with wild-type gag proteins and interferes with the proper formation of the viral core (a trans-dominant effect).

- 5 **Transduction of CD4<sup>+</sup> cells with a minimum HIV-1 vector.** HIV vectors typically have both the 5'- and 3'-LTR. The presence of these regulatory sequences, particularly TAR, interferes with the HIV infection process in transduced cells. V653gpt is too complex for simple analysis of its TAR decoy effect on HIV infection. Therefore, a minimum vector, VOgpt was
- 10 constructed as described. VOgpt includes the two HIV-1 LTRs, the packaging sequences located 5' of the ATG gag initiator, (*i.e.* the three first loops of the main packaging signal), and the SL3-gpt cassette. VOgpt was transfected into the HIV packaging cell line  $\psi$ -422. The supernatant of the stable cell lines obtained (gVO lines) were checked for infectivity
- 15 and for transduction capacity. The virions produced by these cell lines were non-infectious. Ten ng of p24 equivalent of gVO virions did not induce any viral production after a 4-week culture in the presence of Molt4/8 CD4<sup>+</sup> cells. In the same assay, wild-type HIV-1-MN tissue culture infectious dose 50% (TCID<sub>50</sub>) was 10<sup>-3</sup>ng (Table 1). Yet, gVO
- 20 virions were able to transduce Hela-T4 cells -- and not Hela cells -- with a titer ranging from 1.2 to 2.0x10<sup>3</sup> transducing units (TU) per milliliter of supernatant (Table 1). The integrity of the vector in gene altered cells was controlled by Southern blot. Of note, the transduction efficiencies we obtained here with VOgpt are lower than those (*e.g.*, roughly 10<sup>5</sup>TU/ml)
- 25 obtained using V653gpt. The difference between the two vectors is due to the fact that V653gpt contains two sequences in addition to the main packaging signal  $\Psi$  (the 5' portion of *gag*, and the RRE-encompassing fragment of *env*) known to be involved in HIV RNA packaging, and is, therefore, packaged more efficiently than VOgpt.
- 30 **Anti-tat effect of the VOgpt vector.** To examine a TAR decoy effect of VOgpt on tat during the infection of VOgpt-transduced cells, the reporter

plasmid pLTR-CAT, and a tat expression vector, pTAT were used. The amount of CAT protein produced by transduced and non-transduced HeLa-T4 cells after transient transfection with both plasmids. In 3 independent experiments, the amount of CAT protein produced by  
5 VOgpt-transduced cells under tat transactivation was reduced. As a positive control, the same cells were transfected with pCMV-CAT. The production of CAT was the same for the two types of cells, with or without VOgpt-transduction. This implied that, in addition to a TAR decoy effect on the viral tat transactivator, the vector LTR also had a decoy  
10 effect on other viral transcription activators, *i.e.* the constitutive and inducible cellular DNA-binding proteins involved in HIV activation.

The TAR decoy effect on HIV expression was also assessed. HeLa-T4 cells, transduced with VOgpt or untransduced controls, were transfected with a wild-type HIV-1-MN clone, and viral production was  
15 monitored. With two different HIV molecular clone concentrations, a reduction in p24 expression by VOgpt transduced cells, as compared with non-transduced cells was observed. Thus, TAR decoy effects shown for VOgpt were responsible for inhibition of HIV expression in transduced cells. anti-viral agents such as anti-HIVribozymes add to this inhibitory  
20 effect.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually  
25 indicated to be incorporated by reference in its entirety for all purposes. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be  
30 made thereto without departing from the spirit or scope of the appended claims.

WHAT IS CLAIMED IS

1. A high efficiency packaging vector comprising a first high efficiency packaging vector nucleic acid, which first high efficiency packaging vector nucleic acid encodes a first portion of an HIV-1 particle,  
5 wherein:
  - the particle comprises reverse transcriptase activity, and is non-infectious;
  - the first high efficiency packaging vector nucleic acid, when transfected into a cell, renders the cell competent to package HIV-  
10 packageable RNA with a titre of at least  $10^4$  transducing units per ml, wherein the HIV-packageable RNA comprises an HIV-1 packaging site;
  - the first high efficiency packaging vector nucleic acid comprises a deletion of more than one stem loop of the  $\Psi$  structure as compared to a wild-type genomic HIV nucleic acid; and,
  - 15 the first high efficiency packaging vector nucleic acids comprises the *vpr* accessory gene of HIV-1.
2. The vector of claim 1, wherein the first high efficiency packaging vector nucleic acid stably transfects Hela cells.  
20
3. The vector of claim 1, wherein the first high efficiency packaging vector nucleic acid is derived from an HIV-1-MN clone.
4. The vector of claim 3, wherein the first high efficiency  
25 packaging vector comprises clone  $\Delta\Psi$ .
5. The vector of claim 1, wherein the first high efficiency packaging vector nucleic acid comprises a 5' HIV-1 LTR, and wherein the deletion in the  $\Psi$  structure is between the 5' LTR and the GAG gene as  
30 compared to a wild-type HIV-1 virus.

6. The vector of claim 1, wherein the high efficiency packaging vector nucleic acid comprises a heterologous promoter.

7. The vector of claim 1, wherein the high efficiency  
5 packaging vector packages the packaging vector nucleic acid at a level less than 10% of the level that it packages a nucleic acid which comprises a wild-type HIV packaging site.

8. The vector of claim 1, wherein the cell transduced by  
10 the high efficiency packaging vector comprises a second high efficiency packaging vector nucleic acid, which second high efficiency packaging vector nucleic acid encodes components of an HIV particle, wherein the first and second high efficiency packaging vector nucleic acids are complementary.

15

9. A cell comprising the vector of claim 1.

10. The cell of claim 9, further comprising a nucleic acid encoding a VSV protein.

20

11. The cell of claim 9, further comprising a VSV protein.

12. The cell of claim 9, further comprising an HIV-packagable nucleic acid.

25

13. The cell of claim 9, further comprising a nucleic acid encoding an RNA from a virus other than HIV-1.

14. The cell of claim 9, further comprising an HIV-packagable nucleic acid, wherein expression of the HIV packagable nucleic  
30 acid in a cell inhibits HIV replication in the cell.

15. A high efficiency HIV-1-MN based packaging vector comprising a high efficiency packaging vector nucleic acid derived from an HIV-1-MN viral clone, which high efficiency packaging vector nucleic acid hybridizes to an HIV-1-MN nucleic acid under stringent conditions,  
5 wherein:

the high efficiency packaging vector nucleic acid encodes proteins which package HIV-1-MN nucleic acids;

the high efficiency packaging vector nucleic acid encodes the *vpr* HIV-1 accessory gene; and,

10 the high efficiency packaging vector has a deletion which encompasses more than one stem loop from the  $\Psi$  structure.

16. A cell comprising the vector of claim 15.

15 17. The cell of claim 16, wherein the cell further comprises a nucleic acid encoding a VSV envelope protein.

18. The cell of claim 16, wherein the cell further comprises a VSV envelope protein.

20

19. The high efficiency HIV-1-MN based packaging vector of claim 15, wherein the packaging vector comprises the  $\Delta\Psi$  plasmid.

20. A high efficiency HIV packaging cell line which  
25 produces at least about  $10^4$  transducing HIV vector particles per ml, wherein the cell line is stable and non-infectious.

21. The high efficiency packaging cell line of claim 20, wherein the cell line comprises HIV-1-MN derived nucleic acids.

30

22. The high efficiency packaging cell line of claim 20, wherein the cell is a Hela cell.

23. The high efficiency packaging cell line of claim 20,  
5 wherein the cell line is  $\Psi$ -422.

24. The high efficiency packaging cell line of claim 20, wherein the cell line comprises a nucleic acid from a virus other than HIV.

10 25. The high efficiency packaging cell line of claim 24, wherein the nucleic acid encodes a VSV envelope protein.

26. A packaging cell supernatant comprising non-virulent HIV particles comprising an HIV-packageable nucleic acid, wherein the  
15 particles are present at a concentration of at least about  $10^4$  transducing units per milliliter.

27. The packaging cell supernatant of claim 26, wherein the particles comprise a nucleic acid encoding v653gpt.  
20

28. The packaging cell supernatant of claim 26, wherein the particles comprise an HIV packageable nucleic acid which, when expressed in a cell, inhibits HIV replication in the cell.

25 29. A nucleic acid encoding a nucleic acid selected from the group consisting of v653gpt, VOgpt, a  $\Delta\Psi$  packaging plasmid, and a conservative modification thereof.



**30.** A cell supernatant comprising an HIV-based vector produced by a method comprising the steps of:

- (a) incubating a target nucleic acid in a packaging cell line, which packaging cell line comprises a packaging vector nucleic acid which  
5 encodes an HIV-1 particle, wherein
- (i) the particle, when expressed, comprises reverse transcriptase activity;
  - (ii) the particle, when expressed, is non-infectious;
  - (iii) the particles are competent to package RNA with a titre  
10 of at least  $10^4$  transducing units per ml, wherein the RNA comprises an HIV-1 packaging site;
  - (iv) the particles do not package the packaging vector nucleic acids as detected by RT-PCR;
  - (v) the packaging vector comprises a deletion of more than  
15 one stem loop of the  $\Psi$  structure; and,
  - (vi) the packaging vector comprises the Vpr accessory genes of HIV-1;
- thereby packaging the target nucleic acid in an HIV-1 particle, producing a packaged target nucleic acid; and,  
20 culturing the cells to produce a cell supernatant.

**31.** The composition of claim 30, wherein the packaging cell comprises a retroviral nucleic acid from a virus other than HIV-1.

- 25 **32.** A method of producing cells which efficiently package transducing HIV vector particles, comprising:
- introducing a high efficiency HIV-1-MN based packaging vector into a cell, thereby creating a packaging cell;
  - introducing a target HIV packageable transducing nucleic acid  
30 into the cell, and
  - incubating the cells under conditions which permit efficient

packaging of the target packageable nucleic acid into HIV particles, thereby efficiently packaging target HIV vector particles.

33. The method of claim 32, wherein the HIV-1-MN based  
5 packaging vector comprises the  $\Delta\Psi$  plasmid.

34. The method of claim 32, wherein the HIV-1-MN based  
packaging vector stably transforms the cell to make the packaging cell  
prior to the introduction of the target packageable nucleic acid into the  
10 packaging cell.

35. A method of transducing a target cell with a target  
packageable nucleic acid, comprising:

(a) incubating the target nucleic acid in a packaging cell line, which  
15 packaging cell line comprises a packaging vector nucleic acid which  
encodes an HIV-1 particle, wherein

- (i) the particle, when expressed, comprises reverse transcriptase activity;
- (ii) the particle, when expressed, is non-infectious;
- 20 (iii) the particles are competent to package RNA with a titre of at least  $10^4$  transducing units per ml, wherein the RNA comprises an HIV-1 packaging site;
- (iv) the particles do not package the packaging vector nucleic acids as detected by RT-PCR;
- 25 (v) the packaging vector comprises a deletion of more than one stem loop of the  $\Psi$  structure; and,
- (vi) the packaging vector comprises the Vpr accessory genes of HIV-1;

thereby packaging the target nucleic acid in an HIV-1 particle,  
30 producing a packaged target nucleic acid; and,

(b) incubating the target cell with the packaged target nucleic acid,

thereby transducing the target cell with the target nucleic acid.

36. The method of claim 35, wherein the target cell is a CD4<sup>+</sup> cell.

5

37. The method of claim 35, wherein the packaged target nucleic acid comprises an HIV Psi site and, optionally, further comprises an HIV subsequence selected from the group consisting of an HIV LTR, an HIV RRE, and a portion of an HIV *gag* gene.

10

38. The method of claim 35, wherein transducing the cell with the packaged target nucleic acid inhibits HIV replication in the target cell.

15

39. The method of claim 35, wherein the packaged target nucleic acid comprises an HIV LTR.

40. The method of claim 35, wherein the target cell, when transduced by the target nucleic acid, is resistant to HIV infection.

20

41. The method of claim 35, wherein the packaging cell line is stably transduced by the packaging vector nucleic acid before the target nucleic acid is incubated in the packaging cell line.

25

42. The method of claim 35, wherein the target nucleic acid encodes a viral inhibitor.

43. A cell transformation vector comprising an HIV-2 packaging site nucleic acid and an HIV-1 *gag* protein.

30

44. The vector of claim 43, wherein the vector further comprises a VSV envelope protein.

45. The vector of claim 43, wherein the vector further  
5 comprises an HIV-2 LTR.

46. The vector of claim 45, wherein the HIV-2 LTR is derived from HIV-2<sub>KR</sub>.

10 47. The vector of claim 43, wherein the vector further comprises an MPMV nucleic acid nuclear export subsequence.

48. The vector of claim 43, wherein the vector further comprises a transcription cassette, which transcription cassette comprises  
15 a heterologous promoter which directs expression of a nucleic acid of interest.

49. The vector of claim 48, wherein the expression cassette is located in an HIV LTR.  
20

50. The vector of claim 48, wherein the expression cassette is located in a first HIV LTR, and wherein the vector further comprises a second expression cassette located in a second HIV LTR.

25 51. The vector of claim 50, wherein the vector further comprises a third expression cassette located between the first HIV LTR and the second HIV LTR.

52. The vector of claim 48, wherein the nucleic acid of  
30 interest encodes a ribozyme which specifically cleaves an HIV nucleic acid.

53. The vector of claim 48, wherein the promoter is a pol  
III promoter.

54. The vector of claim 48, wherein the promoter is a t-  
5 RNAval promoter.

55. A method of transforming a cell, comprising contacting  
the cell with the vector of claim 43.

10 56. The method of claim 55, wherein transforming the cell  
with the vector renders the cell resistant to HIV infection.

57. The method of claim 55, wherein cell is a CD34<sup>+</sup> stem  
cell.

15

58. The method of claim 55, wherein the method further  
comprises the step of isolating the cell from a mammal prior to contacting  
the cell with the vector, and further comprises the step of introducing the  
cell into the mammal after the step of contacting the cell with the vector.

20

1/6




FIG. 1




FIG. 4




FIG. 5

2/6





FIG. 2

SUBSTITUTE SHEET (RULE 26)

3/6

FIG. 3



SUBSTITUTE SHEET (RULE 26)







FIG. 6

SUBSTITUTE SHEET (RULE 26)

5/6



**FIG. 7**  
**SUBSTITUTE SHEET (RULE 26)**

6/6




FIG. 8A




FIG. 8B

SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/05272**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : Please See Extra Sheet.

US CL : 514/44; 435/ 172.3, 320.1, 375; 536/23.1; 424/93.2

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/44; 435/ 172.3, 320.1, 375; 536/23.1; 424/93.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, CAPLUS, BIOSIS, CA, EMBASE, WIPDS, USPATFUL, APS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	RICHARDSON et al. Packaging of Human Immunodeficiency Virus Type 1 RNA requires cis-Acting Sequences outside the 5' Leader region. J. Virol. July 1993, Vol. 67, pages 3997-4005, see entire document.	1-58
Y	LORI et al. Effect of Reciprocal Complementation of Two Defective Human Immunodeficiency Virus Type 1 (HIV-1) Molecular Clones on HIV-1 Cell Tropism and Virulence. JOURNAL OF VIROLOGY, September 1992, Vol. 66, No.9 pages 5553-5560, see entire document.	1-14
Y	RIZVI et al. Simian Immunodeficiency Virus RNA Is Efficiently Encapsidated by Human Immunodeficiency Virus Type 1 Particles. JOURNAL OF VIROLOGY May 1993, Vol. 67, No.5 pages 2681-2688, see entire document.	1-58

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

13 JUNE 1997

Date of mailing of the international search report

31 JUL 1997

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ABDUR RAZZAQUE

Telephone No. 703-308-0196

Form PCT/ISA/210 (second sheet)(July 1992)\*

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/05272

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SHIMADA et al. Targeted and Highly Efficient Gene Transfer into CD4+ Cells by a Recombinant Human Immunodeficiency Virus Retroviral Vector. Journal of Clinical Investigation. September 1991, Vol. 88, pages 1043-1047, see entire document.	1-58
Y	CARROLL et al. A Human Immunodeficiency Virus Type 1 (HIV-1)-Based Retroviral Vector System Utilizing Stable HIV-1 Packaging Cell lines. J. Virol. September 1994, Vol. 68, No.9. pages 6047-6051 see entire document.	1-58
Y	CLEVER et al. RNA Secondary Structure and Binding Sites for gag Gene Products in the 5' Packaging Signal of Human Immunodeficiency Virus Type 1. J. Virol. April 1995, Vol. 69 No.9 pages 2101-2109 see entire document.	1-58
Y	ALDOVINI et al. Mutations of RNA and Protein Sequences Involved in Human Immunodeficiency Virus Type 1 Packaging Result in Production of Noninfectious Virus. J. Virol. May 1990, Vol. 64, No.5 pages 1920-1926 see entire document.	1-58

Form PCT/ISA/210 (continuation of second sheet)(July 1992)\*

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/05272

## A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

AOIN 43/00, 43/04; A61K 48/00; C12N 15/00, 15/09, 15/63, 15/70, 15/74, 5/00; CO7H 21/02, 21/04